

APPENDIX A

June 14, 2023, ACC Comments on Draft Cancer Inhalation Unit
Risk Factor (IUR) for Ethylene Oxide submitted to OEHHA



June 14, 2023

Submitted via Email: Kannan.krishnan@oehha.ca.gov

Office of Environmental Health Hazard Assessment
California Environmental Protection Agency
1001 I Street, 12th Floor
Sacramento, California 95814

Re: ACC Comments on Draft Cancer Inhalation Unit Risk Factor (IUR) for Ethylene Oxide

Dear Dr. Krishnan,

The Ethylene Oxide Panel (EO Panel) of the American Chemistry Council appreciates the opportunity to provide comments on the OEHHA's proposed Cancer Inhalation Unit Risk Factor for ethylene oxide (EtO) and its accompanying Draft Technical Support Document (Draft IUR). The EO Panel includes the major producers and users of EO in North America.

The Draft OEHHA IUR adopts the US EPA IUR and rejects the TCEQ IUR. We urge OEHHA to reconsider this decision and, at a minimum, to revise the Draft IUR Technical Support Document to address errors and other issues impacting the dose-response assessment of the NIOSH lymphoid mortality and breast cancer incidence data.

EPA's selection of the final IRIS model was based on a questionable statistical analysis and assessment of visual fit in relation to the categorical (grouped) model estimates. Unfortunately, the Draft IUR's acceptance of EPA's EtO IRIS 2016 methodology and assumptions results in the same errors and flaws leading to an implausible IUR and Residual Risk Specific Concentration (RSC). While OEHHA admirably attempts to conduct an "independent" evaluation of bias in EPA's model and the NIOSH epidemiological data, their efforts are based on assumptions in the absence of access to the actual data being considered and repeats EPA's faulty reasoning.

As OEHHA correctly points out, the IRIS IUR is based on both lymphoid mortality and breast cancer incidence from the study by the National Institute of Occupational Safety and Health (NIOSH), whereas the TCEQ IUR is based on lymphoid mortality alone. As discussed in our

detailed comments, the unavailability and incomplete ascertainment of the breast cancer data precludes the use of the NIOSH breast cancer data for quantitative risk assessment purposes. The weaker evidence of causation for breast cancer in the epidemiology studies further supports focus on lymphoid cancers from the NIOSH study. However, the major reasons for the large difference in magnitude between the two IURs are (a) the type of exposure-response model used to fit the epidemiologic data and (b) the interpretation and value of information in related epidemiological and biological evidence to inform the selection of the model.

The Description of the NIOSH and Union Carbide Corporation (UCC) cohort studies need to be corrected

The epidemiological evidence indicates that the NIOSH and Union Carbide Corporation (UCC) EtO Cohort studies are comparable in terms of the number of lymphoid cases (an important factor to consider in the power of the study) and the exposure assessment. While we do not dispute the use of just the NIOSH study to derive the IUR for EtO, the Draft IUR description of the strength and weaknesses of these two studies should be corrected so that both of the studies can inform the selection of the exposure-response model.

Specifically, the Draft IUR should be corrected to limit the description of the NIOSH study exposure assessment as “high quality” and “validated” to apply only to the narrow exposure period after 1978 when data were available to validate the exposure regression model. Prior to 1978, there was very limited or no exposure data available. Furthermore, the model validated after 1978 was altered for years prior to 1978 by holding a key variable “calendar year” fixed at the predicted level in 1978. This calendar year variable is described by the authors of the NIOSH exposure model to be a “surrogate for improvement in work practices.” By holding the variable calendar year fixed prior to 1978, the NIOSH exposure model estimates lower exposure in earlier years compared to 1978. No effort was made by the NIOSH authors to independently validate this substantial adjustment to the model prior to 1978.

Bogen et al (2019) addressed this limitation by finding many sources of new information including but not limited to interviews with sterilizer operators and managers. Independent of any modeling effort, Bogen et al (2019) cited several references from the 1950’s -70’s which provided clear evidence that there were changes in work practices prior to 1978 that did not support holding the variable calendar year fixed prior to 1978. Ironically, the draft IUR dismisses the Bogen et al (2019) model showing the opposite but more plausible trend for historical exposures (e.g., higher exposures in earlier years) because “*the authors were unable to validate their pre-1978 predictions since no actual worker measurement were available from that time*”, and thus, “*the accuracy of the Bogen et al. (2019) assessment is unknown to OEHHA.*”

By the same reasoning, OEHHA should also conclude that the accuracy of the NIOSH model prior to 1978 is unknown, and OEHHA should indicate that the data NIOSH used to develop the model are no longer available (lost) (EPA IRIS, 2016, Appendix H, p H-28).

In contrast, the UCC exposure estimates are superior in quality to the NIOSH exposure estimates because exposure data for the most recent periods, 1957-1973 and 1974-1988, were available for more than 75% of the cohort based on routine monitoring, personal sampling and a plant wide survey in another UCC plant using the same process (Greenberg et al., 1990; Teta et al., 1993; Swaen et al., 2009). Accordingly, at a minimum the NIOSH study needs to be downgraded with respect to these earlier exposure periods and the UCC study needs to be more fully integrated.

These corrections are necessary for a more balanced consideration by OEHHA of both the NIOSH and UCC studies in selecting the most appropriate exposure-response model. The evidence from both of these studies, individually and combined, do not support selection of a 2-slope exposure-response model with a very steep initial slope. The log-linear exposure-response model is far more consistent with the weight of evidence from the NIOSH and UCC studies as described in greater detail in this submission.

Biological and epidemiological evidence should play a primary role in selecting the exposure-response model

The dose-response model used by IRIS (2016) for both breast cancer and lymphoid is a “supralinear¹” two-slope linear spline model (2-slope model), suggesting that risk increases sharply at low exposures and less steeply at higher cumulative exposures above 1600 ppm-days for lymphoid cancer and 5750 ppm-days for breast cancer incidence. In contrast, the dose-response model used by TCEQ (2020a) is the standard² log-linear Cox Proportional Hazards (CPH) model, which is virtually linear at relevant exposure concentrations for estimating cancer risk for the general population³.

The steep initial slope of the USEPA IRIS (2016) supralinear two-slope spline model, which gives rise to one of the highest inhalation cancer potency estimates derived by IRIS, is not justified based on the relatively weak epidemiological findings reported in the original NIOSH peer-reviewed publications, the weight of evidence in the epidemiological literature including the UCC cohort, and the biological evidence in cancer bioassays and analysis of genotoxicity data.

Our comments provide evidence that the TCEQ model is more consistent with epidemiological evidence and has greater biological plausibility than the IRIS model. While the IRIS assessment includes summaries of genotoxicity, toxicology, epidemiology and toxicokinetics, there is no integration of these important lines of evidence into the final quantitative risk assessment process. Instead, the IRIS dose response assessment is driven by exhaustive statistical modeling analyses divorced from consideration of dose-response concordance with genotoxicity,

¹ EPA IRIS uses the term “supralinear” to describe the exposure-response relationship. Ironically, EPA (2022) attributes “supralinear” to ACC as if this is not an appropriate description.

² EPA (2022) attributes the term “standard” to ACC to describe the CPH model TCEQ uses, yet this is the correct term EPA IRIS (2016) uses to describe the log-linear CPH model

³ EPA (2022) correctly acknowledges on p.57 that “the log linear Cox model is essentially linear in the low dose range”.

toxicology and epidemiological weight-of-evidence. Similarly, OEHHA makes no attempt to integrate the different lines of evidence to inform selection of the dose-response.

The EPA (2005) carcinogen risk assessment guidelines states:

“Another problem occurs when a multitude of alternatives are presented without sufficient context to make a reasoned judgment about the alternatives. This form of model uncertainty reflects primarily the availability of different computer models and not biological information about the agent being assessed or about carcinogenesis in general. In cases where curve-fitting models are used because the data are not adequate to support a toxicodynamic model, there generally would be no biological basis to choose among alternative curve-fitting models. However, in situations where there are alternative models with significant biological support, the decisionmaker can be informed by the presentation of these alternatives along with their strengths and uncertainties.”

Similarly, the EPA SAB (2015) emphasized that “any model that is to be considered reasonable for risk assessment must have a dose-response form that is both biologically plausible and consistent with the observed data.” Thus, the epidemiological weight of evidence should play a very important role in the consideration of the model selection. The absence of findings in the UCC study at any exposure, and absence of statistically significant findings at lower exposures in males in the NIOSH study are more consistent with a standard CPH model than an extremely steep initial exposure-response slope.

In the most recent EPA (2022) response to public comments regarding this lack of consideration of the biological evidence in the dose-response assessment, EPA conducts a highly subjective visual inspection of genotoxicity and cancer bioassay data to support its claim that the biological evidence cannot be used to inform biological plausibility. The EPA (2022) evaluation involved (a) plotting the data as point estimates without error bars, (b) drawing a straight line between the response levels for the lowest and highest dose levels and (c) declaring the dose-response to be supralinear or sublinear depending on whether the responses for the mid-dose levels visually appeared to be above or below the line. This visual inspection did not involve any consideration of statistical significance or evaluation of which data set and dose regimen is most relevant and useful to inform epidemiology data based on cumulative exposures. Our comments explain why a single slope CPH model linear at lower exposures that gradually increases at higher exposure is more consistent with the epidemiological, toxicological, and genotoxicity evidence compared to a 2-slope model with a very steep initial slope leading to derivation of one of the highest EPA IRIS IURs.

The Proposed NSRL model selection criteria is based on flawed statistics and visual fit analysis

The Draft IUR reiterates the EPA IRIS (2016) rationale for selecting the 2-slope model based on statistical and visual fit, without considering important new information that was available in the final TCEQ (2020a) DSD and in TCEQ (2020b) response to comments. For example, *OEHHA reports a p-value of 0.01 for EPA’s 2-slope model for breast cancer, suggesting that OEHHA is unaware that statistics literature as well as independent peer reviewers of the TCEQ Development Support Document (DSD) with strong statistical backgrounds agreed with TCEQ that the p-values for the 2-piece spline models were incorrectly calculated.* The corrected p-values are summarized in Table 1 and indicate that there is no statistical basis to select the 2-slope model over the CPH model. Our comments provide ample evidence for why OEHHA’s Draft TSD should report corrected p-values for lymphoid mortality and breast cancer incidence. Table 1. Corrected p-values for IRIS 2-slope linear spline and IRIS standard CPH model

	EPA IRIS (corrected) 2-slope linear spline	EPA IRIS Standard CPH Model
Lymphoid Mortality	P=0.14 corrected from 0.07	P=0.22
Breast Cancer Incidence	P=0.04 corrected from 0.01	P=0.02

Source: Corrected and IRIS reported p-values are based on IRIS (2016; Tables 4-2, 4-4, 4-6, 4-12, 4-13, Appendix D) and Final TCEQ DSD (2020a).

The draft OEHHA IUR includes mistakes with visual fit comparisons made in the IRIS (2016) assessment by stating the following:

“Other models, including the log-linear models (e.g., Cox regression) and the models using categorical data or exposure transformation, generally resulted in slopes that appear to dramatically over- or under-predict the actual study results, especially in the lower-exposure ranges.”

OEHHA makes two errors in this statement:

First, OEHHA incorrectly equates the “actual study results” for lymphoid cancers with the 5 categorical modeled estimates which appear as filled purple dots in IRIS Figure 4-3 and the draft OEHHA IUR Figure 6 with the first “dot” at the origin representing the lagged-out group considered to have zero exposures. Categorical rate ratios (RR) are calculated with respect to a baseline background hazard rate that is also estimated non-parametrically (i.e. not estimated by the CPH procedure). For the continuous models, the actual data modeled are the individual hazard rates not represented graphically in EPA IRIS figures. For example, for lymphoid cancers, there are 53 individual hazard rates-

each reflecting comparisons between one lymphoid mortality case against a risk set of “control” workers defined as those who survived to at least the age of the index case⁴.

The risk set of “control” workers includes both exposed and unexposed workers and is different for each of the 53 lymphoid mortality cases. These “control” risk sets are different from the underlying background hazard rate implied by the nonparametric relative rate (or rate ratios; RR) represented by EPA IRIS as the first categorical purple “dot” at the origin. The true (or implicit) y-intercept (or baseline hazard rate at cumulative exposures) for each continuous model applied to the 53 individual hazard rates will be normalized to 1 at zero lagged exposure⁵. The higher the implicitly modeled y-intercept, the lower the graph will appear on a graph of RR.

Second, OEHHA makes the mistake of assessing whether various models underestimate or overestimate the “actual study results” by making subjective comparisons along the y-axis in direct contradiction to the warning note EPA IRIS and OEHHA included in the figure legends: *“Note that, with the exception of the categorical results, the various models have different implicitly estimated baseline risks; thus, they are not strictly comparable to each other in terms of RR values (i.e., along the y-axis).”*⁶ In other words, it is impossible to make conclusions about over- or under- predicting the actual study results even if one were to incorrectly define the “actual data” as the 5 categorical RR estimates. As explained above, this is because the baseline background hazard rates implied by the nonparametric (categorical) RRs and the underlying background hazard rates implied by the parametric models are generally different, but when graphed as RR values are all normalized to 1 making it impossible to make any conclusions about under- or over-estimations.

Valdez-Flores and Sielken (2013) and TCEQ (2020a) explain in greater detail why OEHHA’s and EPA IRIS’s visual fit approaches are inappropriate because it cannot be assumed that summary RRs describe the true underlying exposure–response relationship for the continuous models. The SAB 2007 implied the same recommendation against visual fit when it instructed EPA to use the individual data to fit the dose-response models. The SAB 2007 concluded “The Panel was unanimous in its recommendation that the EPA develop its risk models based on direct analysis of the individual exposure and cancer outcome data for the NIOSH cohort **rather than the approach based on grouped data** that is presently used.”[emphasis added].

⁴ See IRIS (2016) Appendix D p. D-3, D-69. Note that EPA relied on Steenland et al. 2004 assumption that 100 randomly picked “controls” from the risk set is representative of the full risk set. In contrast, TCEQ (2020a, p. 51) more accurately utilized the full risk set each possibly having more than 17,000 individuals in the risk set for each case.

⁵ Allison (2010), a practical guide to survival analysis using SAS, explains that the intercept is part of the arbitrary function of time, which drops out of the estimating equations”.

⁶ IRIS (2016) Figures 4-2, 4-3, 4-4, 4-5, 4-6, 4-7, 4-9 for lymphoid and breast cancers

The OEHHA Proposed NSRL should reconsider TCEQ’s objective method for assessing model fit based on theoretical concerns that were addressed, instead of relying on incorrect statistical and visual fit methods

Compared to the IRIS and OEHHA visual “eyeballing” comparisons using graphs that are not fit for this purpose, TCEQ (2020a) provided a more objective method to check how well each of the two models (i.e., the standard CPH model⁷ and the 2-piece spline model⁸) applied to general population background cancer rates predicted the number of lymphoid cancer deaths (the key cancer endpoint) that were actually observed in the NIOSH cohort. Table 2 compares the number of lymphoid cancer deaths that were observed in the NIOSH cohort versus the predictions by the IRIS and TCEQ models. In this model ground-truthing exercise, the TCEQ model was not only able to better predict the actual total number of lymphoid cancers in the NIOSH cohort but also the number of cancers in Quintile 2,⁹ demonstrating superior global and local fit below the knot. This approach used to predict cancer deaths from the model is essentially the same well-accepted approach IRIS (2016, Section 4.7) used to estimate extra risk for various occupational exposure levels by applying the IRIS model to the general population background cancer rates in the life-table program.

Table 2. Comparison of observed versus predicted number of lymphoid cancer deaths in NIOSH study using IRIS and TCEQ models

	Observed	Predicted (95% CI)	
		2-piece linear spline model with knot	Standard log-linear CPH model (linear at POD of 1/100 and below)
Total number of cancer deaths	53	91.69 (70.1, 122.4)	52.42 (40.1, 70.0)
Quintile 2 ⁸ cancer deaths	11	20.9 (11.7, 42.0)	14.4 (8.1, 28.9)

Source: TCEQ (2020a) Appendix 3 Table 29 and 30

OEHHA dismissed TCEQ’s prediction method based on an unsupported vague claim that the analysis is flawed because it does not account for differences that might exist between the general US population and the NIOSH worker cohort. Epidemiologic literature has shown that a healthy worker effect (HWE) is predominantly related to workers with shorter follow-up and non-cancer causes (Monson, 1986; Fox and Collier, 1976). Most importantly, the NIOSH study authors themselves concluded that there was unlikely to be a cancer HWE in this longer follow-

⁷ TCEQ’s model using 15-yr lag and the full risk set

⁸ EPA IRIS model using 15-yr lag and 100 workers randomly selected individuals from each case’s risk set

⁹ TCEQ (2020a) defined Quintile 1 as the 9 lagged-out cases (no exposures). The remaining 44 cases were equally divided into 4 groups designated by TCEQ as Quintiles 2-5. EPA IRIS (2016, p. 4-15) reported 13 exposed cases below the knot of 1600 ppm-days. Thus, prediction of Quintile 2 comprised of 11 cases with the lowest exposures best reflects “local” fit below the knot.

up study (Steenland et al., 2004¹⁰). Their conclusions are consistent with that of the International Agency for Research on Cancer textbook on Cancer Epidemiology: Principles and Methods (IARC, 1999), which specifically notes that HWE “is known to vary with type of disease, being smaller for cancer than for other major diseases, and it tends to disappear with time since recruitment into the workforce.” Thus, it is unlikely that there is a HWE in the NIOSH cohort.

OEHHA did not appear to be aware of the TCEQ DSD¹¹ sensitivity analysis to demonstrate that the TCEQ model still better predicts the overall actual cancers after applying a high HWE of 15-16% for lymphoid cancers. Although one can quibble with the TCEQ’s selection of 15-16% based on *overall*¹² cancer SMRs from a Norwegian worker study with relatively short average follow-up of 11.5 yrs. (Kirkeleit et al., 2013), the larger point is that 15% HWE is a reasonable estimate for differences between the general population and the NIOSH worker cohort given the unlikelihood of a cancer HWE in the NIOSH study (Steenland et al., 2004). Figures 1 and 2 show the TCEQ model better predicts the observed lymphoid deaths than the IRIS model overall, and locally at Quintile 2. **Taken together, the OEHHA IUR should be corrected to indicate that the TCEQ model has excellent overall and local fit based on the TCEQ’s prediction analysis, which considers a possible HWE effect as a reasonable surrogate for differences that might exist between the general US population and the NIOSH worker cohort.**

¹⁰ “The healthy worker effect would seem an unlikely explanation for the lack of cancer excesses in the exposed versus non-exposed comparisons.” (Steenland et al. 2004)

¹¹ TCEQ Section A3.3.2

¹² Kirkeleit et al, (2013) did not find a HWE for lymphoid (SMR of 0.97 for males, 1.07 for females) or breast cancer (SMR of 1.02), but TCEQ conservatively used the overall cancer SMR of 0.85 and 0.84 for male and females workers. It is unknown if the Norwegian workers are representative of the NIOSH sterilizer workers.

Number of Lymphoid Deaths Predicted by Different Models Versus the Observed Number of Lymphoid Deaths in the NIOSH Study




Figure 1. Comparison of Overall Fit of TCEQ and IRIS Models To the NIOSH Study

Note: Confidence intervals (CI's) shown are based on Poisson distribution and are very similar to those calculated by TCEQ (2020a) as described in our detailed comments. These similar results provide additional support for TCEQ's conclusions that the TCEQ model has greater overall fit to the data. (See TCEQ, 2020a)




Figure 2. Comparison of Local Fit of TCEQ and IRIS Models To Quintile 2 of the NIOSH study

Note: CI's shown are based on Poisson distribution and are very similar to those calculated by TCEQ (2020a) as described in our comments. These similar results provide additional support for TCEQ's conclusions that the TCEQ model has greater *local* fit below the knot.

OEHHA makes an incorrect and unsubstantiated claim that the CPH model is sublinear at the point of departure (POD) and is therefore less accurate than a linear model (e.g., first initial linear model before the knot). The standard CPH model is essentially linear over the range of exposures for the NIOSH study, and the POD of 1/100,000 was selected by TCEQ to be within the experimental dose-range. Although EPA also prefers a POD of 1/100, EPA (2022, p. 57) agrees that the CPH model is linear at and below the POD of 1/100: "Given that the log linear Cox model is essentially linear in the low dose range, this choice of the POD would likely not have major effect on bottom line estimates, but the use of such a low POD is not a sound risk assessment practice."

Neither OEHHA nor EPA may have considered that TCEQ's (2020a, Appendix 4) selection of the POD is based on USEPA cancer guidelines (2005 page 1-13) and that the POD should be in the range of the observed data "near the lower end of the observed range, without significant extrapolation to lower doses." The exposure concentration (EC) for an extra risk of 1 in 100 (354,399 ppm-days) using TCEQ's model is outside (above) the range of cumulative exposures

for the male lymphoid mortalities in the NIOSH study. In contrast, the EC for an extra risk of 1 in 100,000 is near the lower end of the observed range of cumulative exposures to EtO, and is consistent with TCEQ and USEPA guidelines (TCEQ 2015, USEPA 2005a) on the selection of a POD at the low-end of the observable range of exposures

Background endogenous and ambient levels of EtO provide important reality checks for model selection. The key assumptions in extrapolating the exposure-response relationships at lower exposures are scientifically valid and are now corroborated by independent data sets.

Background endogenous and ambient levels of ethylene oxide are an important reality check for the TCEQ and IRIS model. **While OEHHA is correct that the potency estimates technically only apply to exposures above endogenous levels, it is implausible that a chemical would be a potent carcinogen at fraction of levels that the body produces through natural processes and also be well within the population variability.** We applaud OEHHA for including a section on endogenous levels. However, we disagree with OEHHA's claim in the toxicokinetic section that the data presented by Kirman et al. (2021) is inadequate to estimate ambient equivalent EtO levels at exposures below occupational.

The linear relationship between HEV adducts and EtO exposures is well-supported by data across a broad range of exposure levels (i.e., ranging from background levels to ~4 ppm in workers). As explained in the comments below, this well-supported linear relationship is also supported by a "forward" analysis suggested by EPA (2022) based on measured EtO concentrations in mainstream cigarette smoke that corroborates the Kirman et al. (2021) linear relationship.

In summary, we urge OEHHA to adopt the TCEQ model for lymphoid cancers or use CPH model estimates from the IRIS assessment and revise the draft IUR proposal and background Appendix to better reflect the following:

- 1. The original NIOSH study upon which OEHHA's IUR is based found no indication of increased risk of lymphoid cancers in males at lower categories of exposures and concluded there were no exposure-related effects in females. The TCEQ dose response model is more consistent with the original findings of the NIOSH mortality study.**
- 2. Breast cancer, like other types of cancers OEHHA considered from both animal and human studies, is a cancer endpoint that deserves consideration in the weight of evidence for cancer classification. However, the NIOSH breast cancer incidence data should not be used for quantitative risk assessment based on substantial under-ascertainment of incident cases reported by Steenland et al (2003) and subsequent risk deficits in the lower exposures.**

- 3. OEHHA’s rationale for supporting EPA IRIS model selection is based on uncritical acceptance of EPA’s statistical analysis that did not account for a systematic statistical search for the knot as an estimated statistical parameter. Independent peer reviewers for TCEQ agreed with TCEQ’s corrections of the statistics, which puts the TCEQ model on par with the IRIS model based on statistical significance alone.**
- 4. The TCEQ dose-response model is more plausible based on the biological and toxicological evidence, and the mode of action.**
- 5. OEHHA repeats IRIS’s visual fit comparisons by comparing (“eyeballing”) whether graphs of different models are above or below the categorical (grouped) estimates to incorrectly conclude that the models over- or underestimate “the data.” EPA IRIS footnotes (repeated in OEHHA’s figure legends) clearly indicate that such comparisons along the y-axis should not be made. OEHHA appears to equate the 5 categorical rate ratios with the 53 rate ratios, and/or assumes that the shape of the exposure-response curve for the actual data can be based on grouping the actual data into 5 categorical rate ratios.**
- 6. OEHHA dismisses TCEQ’s prediction analysis which is a more objective method than visual fit to check how well each of the two models (i.e., TCEQ’s vs EPA’s) applied to general population background lymphoid cancer rates can predict the number of lymphoid cancer deaths (the key cancer endpoint) that were observed in the NIOSH cohort. In this model ground-truthing exercise, the TCEQ model was not only able to better predict the actual total number of lymphoid cancers in the NIOSH cohort but also the number of cancers in every quintile and specifically in the lowest Quintile 2¹³ demonstrating superior global and local fit.**
- 7. OEHHA’s reliance on internal analyses and OEHHA’s exclusion of external analysis is based on a scientifically oversimplified main conclusion that all external analysis should be ignored because it is confounded by HWE. This is contradicted by the NIOSH study authors’ own published conclusions that “the healthy worker effect would seem an unlikely explanation for the lack of cancer excesses in the exposed versus non-exposed comparisons.” Furthermore, OEHHA’s acceptance of conclusions of a more recent paper by Park (2020) that there is a Healthy Worker Survival Effect (HWSE) led OEHHA to support EPA IRIS model. However, the conclusions are not supported by the actual results in the paper.**
- 8. Based on uncritical acceptance of the IRIS evaluation, OEHHA inaccurately exaggerates the reliability of the NIOSH worker exposure estimates prior to 1978.**

¹³ TCEQ (2020a) defined Quintile 1 as the 9 lagged-out cases (no exposures). The remaining 44 cases were equally divided into 4 groups designated by TCEQ as Quintiles 2-5. EPA IRIS (2016, p. 4-15) reported 13 exposed cases below the knot of 1600 ppm-days. Thus, prediction of Quintile 2 comprised of 11 cases with the lowest exposures best reflects “local” fit below the knot.

9. **The Union Carbide Corp. (UCC) cohort should play a prominent role in considering the strength and consistency of the epidemiology data in supporting the IRIS vs. TCEQ IUR. Table 7 and OEHHA's description of this cohort in the text is missing the internal analysis by Valdez-Flores et al. (2010) which included exploration of different exposure metrics and lag times. The absence of findings in the UCC cohort for male LH is not consistent with a steep slope at low concentrations.**

10. **The OEHHA Draft IUR questions the reliability of the Kirman et al. (2021) method of estimating endogenous levels of EtO by favoring speculative uncertainty and tangential information on DNA adducts over the well-documented toxicokinetic and converging evidence from animals and humans as presented by Kirman et al. and independently confirmed by data in Filser and Klein (2018). Endogenous levels greatly exceed the levels to which residents near sterilization facilities may be exposed. While EPA's potency estimate technically only applies to exposures above endogenous levels, it is implausible that a chemical would be a potent carcinogen at levels that the body produces through natural processes.**

11. **OEHHA cites two studies reporting an association between smoking and lymphohematopoietic (LH) cancers published in 2012 (Diver et al., 2012 and Kroll et al., 2012) to discount Kirman et al. (2021) reality checks. These two studies are inconsistent with the lymphoid cancer (NHL, lymphocytic leukemia, multiple myeloma) findings from the NIOSH mortality study (Steenland et al., 2004), upon which IRIS 2016 developed their low exposure high risk model and do not constitute a weight-of-evidence evaluation akin to the Surgeon General report, *The Health Consequences of Smoking —50 Years of Progress* (US DHHS 2014). In addition, OEHHA cites an IARC review associating a positive relationship between tobacco smoking and breast cancer, though not for lymphoid cancer.**

12. **OEHHA's estimated EtO 10^{-5} Risk Specific Concentration provide little utility in managing general population risk if background exogenous exposure isn't considered as an initial reality check. There has been an extensive ambient air measurement campaign over the last several years, including measurements near many sterilizer facilities and at background locations. In many cases, the levels of ethylene oxide far away from sterilizer facilities are similar to the levels near sterilizer facilities. Although the sources of this exogenous background ethylene oxide is currently not fully characterized, what is clear is that, in many cases, residents living near sterilizer facilities are not exposed to higher ethylene oxide than people living far away.**

DETAILED COMMENTS

1. The original NIOSH study upon which OEHHA's IUR is based found no indication of increased risk of lymphoid cancers in males at lower categories of exposures and concluded there were no exposure-related effects in females. The TCEQ dose response model is more consistent with the original findings of the NIOSH mortality study.

Pertaining to IUR p. 12-18, 34-43

The extremely steep dose response model selected by EPA IRIS (2016) and adopted by OEHHA for lymphoid cancer mortality has led to the derivation of an IUR that is among the highest EPA IRIS inhalation IURs for known or likely carcinogens. This is inconsistent with the following original conclusions by the NIOSH study authors regarding both internal and external comparisons (Steenland et al., 2004):

- “There was little evidence of any excess cancer mortality for the cohort as a whole”
- “The healthy worker effect would seem an unlikely explanation for the lack of cancer excesses in the exposed versus non-exposed comparisons”
- “Positive exposure-response trends for lymphoid tumors were found for males only (15-year lag)”
- “It is not known why we find an association for males and not females for haematopoietic cancer. . .there was sufficient variation in the exposure of women to have observed an exposure-response if one existed.

A large number of models were considered by IRIS, including those using log transformation of cumulative exposure, which IRIS (2016) correctly excluded as biologically implausible. Of the models using cumulative exposures, the strongest trend was seen in male lymphoid mortality. As described in detail in the next section, breast cancer incidence is not an appropriate endpoint based on the weight-of-evidence and quality issues. Therefore, of the critical endpoints selected by IRIS, male lymphoid mortality is the most appropriate endpoint for risk assessment, protective of effects in females who showed no sensitivity.

In the internal categorical analysis for male lymphoid tumors, the only statistically significant increase in male lymphoid odds ratio (OR) is only at the highest cumulative exposure level. Were EtO a potent carcinogen as IRIS suggests, one would expect to see a statistically significant increase at these lower cumulative exposures.




Figure 3. Categorical Odds ratios (OR) for males (95% Confidence Intervals):

Note: Male ORs for exposure categories 0 (lagged out), >0-1200 ppm-days, 1201-3680 ppm-days, 3681-13,500 ppm-days, >13,400 ppm-days are, respectively, 1, 0.91 (0.16-5.23), 2.89 (0.65-12.86), 2.71 (0.65-11.55), **3.76 (1.03-13.64)** (EPA IRIS, 2016, Table D-28)

Statistical modeling can take on a life of its own if not checked against epidemiological data which do not indicate an extremely steep low-dose dose response and/or a major discontinuity in the dose response. It is important to keep into perspective that the relevant epidemiology, including a large number of human studies published over a forty-year period, indicates that there is inconclusive evidence of carcinogenicity (IARC 2012a). For example, the UCC study of EtO chemical workers with comparable numbers of lymphoid cancers and substantial exposures to EtO show no increased risk of male lymphoid cancers. The findings from EtO epidemiology conflict with the IRIS risk values which imply EtO is a highly potent carcinogen at lower cumulative exposures. Were EtO a highly potent carcinogen, one would have expected to see a strong signal rather than many studies being inconclusive.

2. Breast cancer, like other types of cancers OEHHA considered from both animal and human studies, is a cancer endpoint that deserves consideration in the weight of evidence for cancer classification. However, the NIOSH breast cancer incidence data should not be used for quantitative risk assessment based on substantial under-ascertainment of incident cases reported by Steenland et al (2003) and subsequent risk deficits in the lower exposures.

Pertaining to IUR p. 20, 35, 39, 45

The primary reason breast cancer should not be included in EtO quantitative exposure response analysis is that there is substantial under-ascertainment of incident cases due to non-participation in the interview study. This raises a serious issue- potential selection bias. The evidence related to causation is weak for breast cancer, supporting the focus on lymphoid cancers for quantitative risk assessment based on the epidemiological data.

Neither the NIOSH breast cancer incidence study (Steenland et al., 2003) nor the NIOSH mortality study (Steenland et al., 2004) report an overall excess of breast cancer. The positive NIOSH findings are not robust in that they are seen with a certain lag and exposure metric that are not evident with numerous other exposure metrics, models, or lags. The breast cancer incidence findings are at most suggestive, not only due to inconsistencies in the exposure-response, but also due to incomplete cancer ascertainment and the subsequent potential for bias. This disease endpoint is only weakly supported by other epidemiology studies and is inconsistent with others.

The IRIS breast cancer incidence analysis relied on data from the subpopulation of the NIOSH cohort that was interviewed, which required both locating subjects and identifying those diagnosed with breast cancer. Of the 7,576 women in the NIOSH cohort, only 5,139 (68%) were included in the interview portion of the study. The percent non-response was of concern, according to the authors. The majority of these, 22%, could not be located and therefore any breast cancer diagnosis would have been missed. Steenland et al. (2003) indicated that cases lost are more likely to be shorter term (i.e., lower cumulative exposure) employees.

Those who work longer (i.e., higher cumulative exposures) stay in the area longer and are more likely to get picked up in the state tumor registries and be found for interview. Shorter duration workers with lower cumulative exposures are more likely to leave the area and not be captured in the overall analyses and less likely to be interviewed. If more cases were missed among those with lower cumulative exposures (shorter term employees), then the data would be biased toward seeing a positive slope and/or elevated risk in the higher exposure groups, as reported by Steenland et al. (2003).

Steenland et al. (2003) stated that “breast cancer ascertainment in the sub-cohort with interviews was considered complete.” In other words, all the women who were interviewed were identified as having breast cancer or not. This, however, does not account for the missing cases among

non-participants in the interview study or for cases never identified in the overall target population. Importantly, there is no way of knowing that the distribution of cases by level of exposure in the subcohort of interviewed breast cancer cases is comparable to the distribution in the fully ascertained total cohort. Due to the greater difficulty of locating women with short term employment, there is a high potential for bias in missing cases at lower cumulative exposure. The rate ratios for breast cancer incidence in the lowest exposed groups in the entire cohort were 0.88 (15 yr. lagged out group) and 0.74 (<647 ppm-days, no lag), the latter of which was a statistically significant deficit (Steenland et al., 2003, Table 3). These deficits contributed to suggested positive trends.

Steenland et al. (2003) made an attempt to investigate possible selection bias but noted he didn't have adequate data to address this concern:

“A second possible bias was the preferential ascertainment of breast cancer among women with stable residence in states with cancer registries; women with stable residency might be expected to have longer duration of employment in companies under study, and hence greater cumulative exposure. Unfortunately, we didn't have residential history, limiting our ability to explore this possibility. (Steenland et al. 2003)”

Without the incidence data, selection bias cannot be properly tested. However, several issues support this explanation: 1) the overall population long-term (higher exposed) women would be easier to identify as having breast cancer as they remain for longer periods in states of employment that have tumor registries, 2) similarly, longer employed and higher cumulative exposure women would be easier to locate and thus interviewed, and 3) duration of employment in Steenland et al. (2003) showed a stronger relationship with breast cancer than did actual cumulative exposure.

Steenland et al. (2003) recognized this limitation as one reason he was tempered in his causation conclusions:

“Our data suggest that ETO is associated with breast cancer, but a causal interpretation is weakened due to some inconsistencies in exposure-response trends and possible biases due to non-response and incomplete cancer ascertainment.”

In summary, the weak association of EtO with breast cancer and the exposure-response uncertainty due to the sizeable number of missing breast cancer cases precludes use of the NIOSH interview data in derivation of IURs. This, together with the unavailability of the breast cancer incidence data to other researchers to independently examine these issues raises quality issues that indicate the data are inappropriate for exposure-response modeling for regulatory cancer risk assessment purposes.

3. OEHHA’s rationale for supporting EPA IRIS model selection is based on uncritical acceptance of EPA’s statistical analysis that did not account for EPA’s systematic statistical search for the knot as an estimated parameter. Independent peer reviewers for TCEQ agreed with TCEQ’s corrections of the statistics, which puts the TCEQ model on par with the IRIS model based on statistical significance alone.

Pertaining to IUR 34, 47

OEHHA accepts EPA IRIS (2016) conclusions on model fit that are based on incorrect statistical analysis and inappropriate visual fit comparisons (described below). TCEQ (2020a) provided corrected AIC and p-values for the spline models that OEHHA could have easily verified were correct. The peer review of TCEQ’s dose-response assessment included two independent reviewers who had strong statistical modeling expertise. Both peer reviewers agreed that EPA incorrectly calculated p-values because they did NOT correct for including the knot as an estimated parameter in the model, a basic violation of statistical principles:

Expert 5: “I do believe that TCEQ has identified a real problem with the USEPA AIC and p-value calculations. The explanation of the issue and the resolution supplied in DSD seems appropriate. That is, I agree with TCEQ that the knot parameter in the spline models should be considered in the count of the parameters, that the AICs reported by USEPA for those models are too low by a value of 2, and that the p-values should be computed using an approximation to a chi-square with 3 degrees of freedom.” (TCEQ 2020b, p. 45)

Expert 6: “I consider that the location of the spline should be considered a parameter when evaluating fits of spline models, as long as the data were used in determining the knot, as it apparently was in EPA’s model. I believe also that the lag should also be considered a parameter when the data are used to determine its value. But, in general, I consider the AIC in such complex models to be essentially only a rough guide to evaluating fit. Therefore, I think TCEQ’s conclusion that the ‘lower AIC means that TCEQ’s selected model is a statistically superior model fit than USEPA’s selected model when taking into account model complexity’ is an overstatement. Comparing a model with an AIC = 464.5 to one with an AIC = 264.4[sic¹⁴], you can only conclude with confidence that the two models fit about equally well. Additionally, the overall fit is not of major importance – the fit at small doses is much more important when the object of the fitting is to estimate the risk at very small doses.” (TCEQ 2020b, p. 50)

The basic principle of accounting for all modeled parameter is clearly articulated in the National Research Council report entitled “Models in Environmental Regulatory Decision Making”, which states that the strategy to pick the “best model” for regulatory decision making should be “subject to a penalty function reflecting the number of model parameters, thus effectively forcing a trade-off between improving model fit by adding addition[al estimated] model parameters

¹⁴ Expert really meant 464.4

versus having a parsimonious description” (NRC, 2007, pp. 174). Importantly, there are no recognized exceptions to the penalty component of the balance incorporated into the AIC metric when applied in a valid procedure for model-selection (Burnham et al., 2002). This general principle is well recognized in the peer reviewed literature to apply specifically to including the estimated “knot” or inflection point from reporting the use of 2-piece linear spline models (Berman et al., 1996, Li et al., 2011; Gkioulekas et al. 2018, Molinari et al., 2001).

EPA ORD incorrectly claims that they fixed the knot and then conducted a sensitivity analysis. However, EPA ORD did not simply “fix” or “select” the position of the knot in that model. Instead, IRIS systematically tested 20 alternative knots for breast cancer and 70 knots for lymphoid mortality, and then among these, selected knot values that maximized the likelihood of data fit to a corresponding 2-piece spline model.

In the EPA IRIS (2016 Appendix D at p. D-13), Dr. Steenland provided statistical analysis considering the knot as a parameter for breast cancer to show this had no substantial effect in that analysis, but a similar examination was not presented in the case of lymphoid cancer. In other words, there was clear acknowledgement and recognition expressed in the IRIS (2016) assessment that each knot value that was used to obtain a final spline-model fit is appropriately interpreted as an estimated parameter. Thus, IRIS should have reported the p-values considering the knot as an estimated parameter for breast and lymphoid cancers in the summary tables of the main report for greater transparency.

OEHHA should revise their discussion of fit of the data to reflect the corrected p-values reported by TCEQ (2020a) for the IRIS selected 2-piece spline provided in Table 1 of our comments above. Based on corrected statistical analysis alone, neither EPA IRIS ($p=0.14$) nor the TCEQ ($p=0.22$) dose-response models for lymphoid cancers provide strong evidence that the exposure-response slope differs from zero. Based on statistics alone, the CPH model fits the data similarly to the supralinear 2-piece spline slope but has the advantage of parsimony (simpler model) and biological plausibility (described below). Also described in greater detail below, the CPH model more accurately predicts the observed lymphoid mortalities overall and at lower exposures in the NIOSH study compared to the IRIS (2016) selected 2-piece spline model.

In addition to Table 1, we suggest OEHHA include Table 3 in their detailed analyses, which provides a more complete and direct comparison between the statistics and IUR derivation for the 2-piece spline model and the CPH model. Table 3 will provide users of OEHHA’s assessment an understanding of the range of values that can be estimated for risk assessment based on the IRIS (2016) preferred methods and assumptions.

Table 3. Comparison of IRIS (2016) derived models (IURs not including the ADAF)

	2-piece linear spline Linear at EPA POD 1/100	Standard CPH Linear at EPA POD 1/100
Model of individual data?	Yes	Yes
IRIS full model name	Linear spline model with knot at 1,600 ppm x days	Log-linear model (standard Cox regression model)
<u>LYMPHOID INCIDENCE (Males and Females)</u>		
IRIS p-value	0.14 corrected from 0.07	0.22
Central estimate IUR (per ppm)	1.34	0.0095
Upper bound IUR (per ppm)	5.26	0.020
<u>BREAST CANCER INCIDENCE (Females)</u>		
IRIS p-value	0.04 corrected from 0.01	0.02
Central estimate IUR (per ppm)	0.71	0.08
Upper bound IUR (per ppm)	1.48	0.14
<i>These data are not appropriate for quantitative risk assessment purposes because authors report substantial number of missing cases with higher potential for those with shorter employment missing (Steenland et al. 2003). These data have not been available for independent evaluation by EPA or the public, and, thus, lack transparency, verification, and independent analysis.</i>		
<u>LYMPHOID & BREAST CANCER INCIDENCE (Males and Females)</u>		
Central estimate IUR (per ppm)	2.1	0.1
Upper bound IUR (per ppm)	6.1	0.15
<i>These data are not appropriate for risk assessment because the breast cancer incidence data are included. EPA provided no justification for the POD of 1/100. TCEQ (2020a) analysis shows that the POD 1/100 for the standard CPH model extrapolates above or in the high range of the experimental data!</i>		

4. The TCEQ dose-response model is more plausible based on the biological and toxicological evidence, and the mode of action.

Pertaining to IUR p 15-18, 20-23

A biological mode of action should be a major consideration when selecting a model for risk assessment.

Currently, genotoxic MoA is considered as a default assumption in the absence of a convincing alternate MoA that does not involve genotoxicity as the initial key event. The dose-response and temporality of EtO induced genotoxicity in the etiology of either animal or human tumors has not been fully vetted through a formal process such as the one recommended by International Program on Chemical Safety (Boobis et al., 2006).

For a direct acting alkylating agent such as EtO, the default dose-response for the induction of mutations is linear. This is the worst-case scenario since at low doses closer to the origin, one should expect cellular protective mechanisms (e.g., detoxification and DNA repair) to offer protection, resulting in a shallower slope in this region when compared to higher doses. Based on a presumed genotoxic MoA, both TCEQ and EPA/OEEHA estimate cancer risk based on a linear extrapolation from the POD to the origin but apply very different statistical models to the same epidemiological study to derive the POD, i.e., Cox proportional hazards (CPH) model by TCEQ vs. the two-piece spline model by the EPA/OEEHA.

In the 2-two-piece spline model, the initial slope rises rapidly at lower exposure levels and then rises more gradually for higher exposures. This type of dose-response is not consistent with the biology of how EtO works as a direct acting genotoxicant. The dose-response curve for EtO-induced gene mutations in the bone marrow (Recio et al., 2004, Figure 4) and lung (Manjanatha et al., 2017, Figure 5) tissues of transgenic Big Blue mice is especially informative since these tissues represent targets for EtO-induced tumors. In both cases, there is no evidence for a steeper initial slope and the dose-response pattern is more consistent with the CPH model than the 2-piece spline.




Figure 4. Dose-Response for EtO-Induced *lacI* mutations in Mouse Bone Marrow (6 h/day; 5 days/week; 48 weeks from Recio et al., (2004)

Recio et al. (2004) observed increases in *lacI* mutant frequency in the bone marrow of transgenic Big Blue B6C3F1 mice at EtO exposure concentrations of 100 and 200 ppm (but not at 25 or 50 ppm) after 48 weeks of exposure. No increases were observed following 12 and 24 weeks of exposure.





Figure 5. Dose-response for the Induction of *cII* mutations in the lung tissue of Big Blue B6C3F1 transgenic mice at 8 weeks of inhalation exposure to EtO (Manjanatha et al., 2017).

Similarly, Manjanatha et al. (2017) investigated exposure-response and temporality for EtO-induced mutations at the *cII* locus in the lung tissue of transgenic Big Blue male B6C3F1 mice exposed to 0, 10, 50, 100, or 200 ppm EtO for 6 hr/day, 5 days/week over 4 weeks (in all exposure groups) or for 8 or 12 weeks (in only the two highest exposure groups). A significant increase was observed only following 8 or 12 weeks of exposure and only at the highest concentration studied (200 ppm), which was twice the tumorigenic concentration used in the NTP (1987) bioassay in the same strain of animal. Contrary to expectations consistent with a mutagenic MOA, no statistically significant increase in mutant frequency or mutational spectrum were observed following 4 weeks of EtO exposure (which is considered to be adequate exposure duration for detecting chemically-induced mutations as per OECD test guideline 488). These results are inconsistent with modified Hill criteria for exposure-response and temporality assuming a mutagenic MOA when considering the NTP (1987) studies in male and female B6C3F1 mice exposed to 0, 50, 100 ppm, 6 hrs/day, 5 days/wk for 102 weeks that were described in the draft IUR (p.7)

The above dose-response patterns are fully consistent with the molecular initiating event(s) leading to EtO-induced mutagenicity, i.e., the formation for DNA adducts. Marsden et al. (2009) using a highly sensitive liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography-accelerator mass spectrometry analysis have shown that the dose-response for the induction of N7-(2-hydroxyethyl)guanine (N7-HEG) adducts in the livers of rats treated with EtO is at best described as linear, with significant increases over the background being observed only at the three higher tested doses.






Figure 6. Dose-response for exogenously derived DNA adducts in liver of [¹⁴C]EtO-treated rats measured by LC-MS/MS (Marsden et al., 2009).

Although the N7-HEG adducts are not considered mutagenic, they are the most abundant DNA adducts formed following EtO exposure (Walker et al., 1992). Thus, the shape of the dose-response curve for the N7-HEG adduct can be considered as the worst-case scenario for EtO-induced adducts, including the most mutagenic O⁶-HEG adduct whose abundance is approximately 300 times lower than that of the N7-HEG adduct (Walker et al., 1992). In reality, the slope for the mutagenic O⁶-HEG adducts is expected to be much shallower than that for N7-HEG because of the kinetics of their formation and repair (Swenberg et al., 2008). Accordingly, the dose-response pattern for the molecular initiating event leading to EtO-induced mutagenicity is expected to be non-linear or at best linear at the low end of the dose-response curve and the efficiency of adduct formation increasing at higher exposure levels due to saturation of the DNA-repair processes.

Further evidence for the implausibility of a steeper initial slope in the EO dose-response comes from genotoxicity and carcinogenicity studies conducted with ethylene. Since ethylene is metabolized in vivo to EtO, it forms the same type of protein and DNA adducts as EtO. Based upon a physiologically based toxicokinetic model, Filser and Klein (2018) predicted that exposures to 10000 ppm ethylene induces adduct levels equivalent to EO exposures of 3.95 (mice), 5.67 (rats), or 0.313 ppm (humans). Ethylene is not an in vivo genotoxicant in the rat or the mouse (Vergens and Pritts, 1994; Walker et al., 2000).

In a chronic bioassay, ethylene was not carcinogenic in male and female Fischer 344 rats following exposed 6 hr/day, 5 days/week, for up to 24 months to concentrations of 300, 1000, or 3000 ppm (Hamm et al., 1984). DNA adducts resulting from 300, 1000 or 3000 ppm ethylene are shown to be quantitatively to 2.4, 5.3 and 5.5 ppm EtO, respectively (Filser and Klein, 2018).

Lack of ethylene carcinogenicity in the rat, in spite of increased DNA adducts equivalent to low ppm-level EtO exposure, informs that the potency of EtO's carcinogen is not higher at the lower exposures, an observation contrary to the prediction based on the IRIS (2016) 2-slope dose response model. On the other hand, the dose-response for EtO carcinogenicity is conservatively consistent with a default linear risk model with a single slope.

Fennell and Brown (2001) showed that blood concentrations of EtO in mice, rats, and humans increased linearly with exposures between 50 and 200 ppm (see figure below). Dose-disproportionate increases in blood EtO occurred only in mice at exposures exceeding 200 ppm and were attributed to substantial depletion of GSH, which limits the overall GSH conjugation capacity. It needs to be emphasized that the dose-disproportionate response in mice involved an increased (not decreased) rate of blood EtO concentration at exposures >200 ppm EtO. These observations do not support the plausibility for a steeper slope at lower exposures either for genotoxicity or carcinogenicity.




Figure 7. Toxicokinetics of EtO from Fennell and Brown (2001).

In conclusion, EtO is a relatively weak genotoxicant and requires relatively high and prolonged exposures to induce mutagenicity. The experimentally observed dose-response patterns for mutagenicity/carcinogenicity show that the CPH model is biologically more plausible than the IRIS (2016) 2-slope model. Accordingly, the CPH model should be the model of choice for risk assessment purposes especially if an alternate model is not a better fit to the observed data.

Qualitative and quantitative analysis of genotoxicity data by Gollapudi et al. (2021) provide independent converging evidence supporting TCEQ's quantitative risk assessment.

The recent literature search conducted by OEEHA missed the publication by Gollapudi et al. (2021). These authors analyzed the dose-response data to identify a point-of-departure for EtO-induced in vivo genotoxicity from an exhaustive list of published studies that employed various endpoints, tissues, and species and derived 238 ppt as the lowest permitted daily exposure (PDE) from this analysis. The PDE of 238 ppt proposed in this publication is more than three orders of magnitude higher than the 0.1 ppt established by the U.S. EPA (2016) and similar to the 240 ppt estimated from TCEQ (2020a) risk values for 1-in-10⁶ (1/M) extra risk. Thus, if EtO were operating through a genotoxic mode of action (MoA) for its carcinogenicity, then the risk assessment model used by the TCEQ, rather than the one used by the EPA, is consistent with the biology based on the analysis by Gollapudi et al., (2020).

Regarding Carlsson et al. (2017) and Zeljezic et al. (2016) genotoxicity study in workers

The results from the studies by Carlsson et al. (2017) and Zeljezic et al. (2016) identified in the recent literature search by OEEHA should be interpreted with caution since the subjects in this study were exposed to multiple carcinogenic/genotoxic chemicals including EtO and hence it is difficult to attribute the effects observed to any single chemical. Accordingly, the statement by OEEHA that the results “..... are consistent with the overall evidence for the genotoxicity of ethylene oxide” is an overstatement.

5. OEHHA repeats IRIS’s visual fit comparisons by comparing (“eyeballing”) whether graphs of different models are above or below the categorical (grouped) estimates to conclude that the models over- or underestimate “the data.” EPA IRIS footnotes (repeated in OEHHA’s figure legends) clearly indicate that such comparisons along the y-axis should not be made. OEHHA appears to equate the 5 categorical rate ratios with the actual 53 hazard rates, and/or assumes that the shape of the exposure-response curve for the actual data can be based on grouping the actual data into 5 categorical rate ratios.

Pertaining to IUR p. 36, 37, 40

OEHHA relies on IRIS’s visual fit comparisons using figures that compare continuous models with categorical models, as if the categorical model with only five points were the gold standard for understanding the shape of the exposure-response curve. While categorical models with a small number of odds ratios can be useful for identifying possible associations, they do not identify the shape of the dose-response curve based on continuous data modeling as shown in detail by Valdez-Flores and Sielken (2013). Based on these visual fit comparisons, OEHHA concludes that models either over or underpredict the categorical model, which are not the data modeled.

TCEQ provided new information that OEHHA may not have been aware of. Graphical display of data is subject to manipulations including the choice of how data are expressed on the y-axis and resolution of categorical models to represent the underlying individual data that were modeled. TCEQ’s purpose is best expressed in response to peer review comments (TCEQ 2020b, p.49. 51):

“The TCEQ only discusses visual fit (and only in an Appendix) because of USEPA’s reliance on it. By contrast, the TCEQ does not rely on visual model fit as a primary consideration for model choice, but rather principally relies on MOAs and various statistical diagnostics of model fit (i.e. AIC and p-values, statistical analyses of model accuracy), consistent with the comment.”

TCEQ’s explains in text and illustrates in figures that EPA’s graphs are misleading because EPA uses the categorical modeling results (which are not the primary data being modeled) to visually evaluate the fit of models as though these cruder categorical estimates represent the true underlying dose response. EPA correctly points out that each of these individual case categories will have very wide confidence intervals (CI) but fails to address TCEQ’s major point which is that the categorical estimates graphed as point estimates without the CI are not representative of the underlying 53 hazard rates modeled. EPA IRIS did not exhibit the wide confidence intervals associated with the EPA’s categorical model in the graphs used to illustrate visual fit. Thus, TCEQ produced similar figures without the CI’s to better illustrate the underlying individual hazard rates that are being modeled. TCEQ explains why comparison of the dose-response model results to the categorical model results is inappropriate on p. 52 of TCEQ’s (2020b) response to the peer review.

“This is because while assessing model fit by visual inspection to the underlying modeled datapoints is a commonly used technique. . . , the dose-response models being judged by visual fit to the categorical results were fit to different data, the more refined individual data. The USEPA should not have used the categorical modeling results (which are not the primary data) to visually evaluate the fit of models to other data (the individual data) as though the cruder categorical data represent the true underlying dose-response.”

EPA counters TCEQ stating that the categorical model is a well-accepted method to represent the data. This true statement is irrelevant to addressing TCEQ’s main point- visual fit based on categorical models are not appropriate for the purpose of determining goodness of fit of the model to the underlying data, because the categorical model is NOT the underlying individual data. TCEQ cites Valdez-Flores and Sielken (2013) which is a peer-reviewed paper that demonstrates how the shape of categorical results can change with different numbers of categories.

TCEQ is not advocating the use of these graphs to assess visual fit as a method to select the models, but instead is informing that these graphs should not be used for visual fit. Instead, TCEQ relies on a more objective statistical modeling approaches to evaluate goodness of fit, rather than “eyeballing” comparisons using figures that are not fit for this purpose and distort the true comparisons of models against the underlying individual data that were modeled.

OEHHA should correct their discussion of visual fit so that all OEHHA’s claims of over or underprediction are omitted, as they violate EPA IRIS’ warning that such comparisons along the y-axis are incorrect comparisons of over or under prediction.

6. OEHHA dismisses TCEQ’s prediction analysis which is a more objective method than visual fit to check how well each of the two models (i.e., TCEQ’s vs EPA’s) can predict the number of lymphoid cancer deaths (the key cancer endpoint). In this model ground-truthing exercise, the TCEQ model was not only able to better predict the actual total number of lymphoid cancers in the NIOSH cohort (with and without an HWE) but also the number of cancers in Quintile 2¹⁵ demonstrating superior global and local fit.

Pertaining to IUR p. 47-48

As described above in our general comments, OEHHA dismissed TCEQ’s “reality check” (Table 4) based on a prediction analysis because the models are applied to general population background cancer rates, which OEHHA considered to be a flawed analysis because the NIOSH study is based on a specific cohort of occupational workers. Yet, this approach is essentially the same approach used by IRIS (2016, Section 4.7) to estimate extra risk for various occupational exposure levels by applying the model to the general population background cancer rates in the life-table program.

Table 4: Total NIOSH Cohort Lymphoid Cancer Mortalities Predicted by TCEQ (2020a) and EPA IRIS (2016) Models

Model (15-yr lag, MLE)	Slope Parameter (per ppm-day)	Predicted if the Model were True	100% × Ratio: Predicted / Observed	100% × SMR: Observed / Predicted	95% Poisson CI if the Model were True
TCEQ (CPH)	2.81E-06	52.42	98.9%	(40.1, 70.0)	(38.2, 66.6)
IRIS 2-slope spline 15-yr lag (MLE)	7.58E-04	91.69	173.0%	(70.1, 122.4)	(72.9, 110.4)

Note: There are 53 actual lymphoid mortalities. 53 is within the CI’s for the TCEQ model but not within the CI’s for the IRIS model. Thus, the TCEQ model accurately predicts the actual cancers. In contrast, the IRIS model statistically significantly (bold font) over-predicts the actual number of cancers. TCEQ used the inverse of the confidence intervals of the SMRs. We calculated the confidence intervals based on the Poisson distributions. TCEQ (2020a, Table 6).

¹⁵ TCEQ (2020a) defined Quintile 1 as the 9 lagged-out cases (no exposures). The remaining 44 cases were equally divided into 4 groups designated by TCEQ as Quintiles 2-5. EPA IRIS (2016, p. 4-15) reported 13 exposed cases below the knot of 1600 ppm-days. Thus, prediction of Quintile 2 comprised of 11 cases with the lowest exposures best reflects “local” fit below the knot.

EPA (2022) also raised a question about TCEQ’s calculation of the confidence interval (CI) based on the inverse of the SMR CI as described in detail by TCEQ (2020a). Thus, it is useful to show that another well-accepted approach for estimating the 95% CI results in the exact same conclusion that the TCEQ model accurately predicts the actual 53 cases, whilst the IRIS model over-predicts the number of cases (Table 4)

OEHHA claims that TCEQ calculations did not accurately account for any differences that might exist between the general US population and the NIOSH cohort. It is unclear if OEHHA is aware that the TCEQ (2020a) DSD¹⁶ includes a sensitivity analysis to demonstrate that the TCEQ model better predicts the overall actual cancers even after applying a high HWE of 15-16% for lymphoid cancers as a sensitivity analysis (Table 5).

Table 5: Total NIOSH Cohort Lymphoid Cancer Mortalities Predicted by TCEQ (2020a) and EPA IRIS (2016) Models with 15% HWE as a Sensitivity Analysis

Model (15-yr lag, MLE)	Slope Parameter (per ppm-day)	Predicted if the Model were True	100% × Ratio: Predicted / Observed	95% Poisson CI if the Model were True
TCEQ (CPH)	2.81E-06	44.56	84.1%	(31.4, 57.6)
IRIS 2-slope spline 15-yr lag (MLE)	7.58E-04	77.94	147.1%	(60.6, 95.2)

Note: The TCEQ model still accurately predicts the actual cancers after accounting for a theoretical HWE. In contrast, the IRIS model statistically significantly (bold font) over-predicts the actual number of cancers after including a theoretical HWE¹⁷. TCEQ used the inverse of the confidence intervals of the SMRs. We calculated the confidence intervals based on the Poisson distributions.

Although one can quibble with the TCEQ’s selection of 15-16% based on a Norwegian worker study with relatively short average follow-up of 11.5 yrs (Kirkeleit et al. 2013)¹⁸, the larger point is that a 15% HWE is a very reasonable high estimate for any differences that might exist between the general US population and the NIOSH worker. The NIOSH study authors themselves concluded that there was unlikely to be a cancer HWE in this longer follow-up study (Steenland et al. 2004¹⁹) cohort. This conclusion of the NIOSH study authors is very consistent with the general experience in cancer epidemiology that HWE is known to vary with type of

¹⁶ TCEQ Section A3.3.2

¹⁷ Predicted is based on multiplying predicted values in Table 4 by 0.85 for HWE of 15%, and CI’s calculated using Poisson distribution. Compare with TCEQ (2020a, p. 102, Section A3.3.2) estimates of 44.3 (95% CI: 33.9, 59.2) and 77.5 (95% CI: 59.3, 103.6) based on 15 and 16% HWE for males and females, respectively.

¹⁸ Kirkeleit et al (2013) did not find a HWE for lymphoid or breast cancer. It is unknown if the Norwegian cohort is representative of the NIOSH sterilizer workers.

¹⁹ “The healthy worker effect would seem an unlikely explanation for the lack of cancer excesses in the exposed versus non-exposed comparisons.” (Steenland et al. 2004)

disease, being smaller for cancer than for other major diseases, and it tends to disappear with time since recruitment into the workforce (IARC, 1991). In addition, the epidemiologic literature has shown that a HWE is predominantly related to populations with shorter follow-up and non-cancer causes (Monson, 1986; Fox and Collier, 1976).

Using a 15% HWE, the CPH model statistically estimates the observed number (53) of lymphoid deaths in the NIOSH study (Table 5). In contrast, the linear 2-piece spline model statistically significantly overestimates the number of observed lymphoid deaths in the NIOSH study (Table 5). In addition, a quintile analysis was also performed by TCEQ (2020a) to address EPA IRIS (2016) emphasis on the local fit of the models below the knot. EPA IRIS (2016, p. 4-15) reported 13 exposed cases below the knot of 1600 ppm-days. Thus, prediction of Quintile 2 comprised of 11 cases best reflects “local” fit below the knot. Table 6 summarizes TCEQ CPH and EPA 2-piece spline model predictions of the number of lymphoid deaths at each quintile. Table 6 shows that for each quintile, the CPH model has superior local fit. These results indicate that the CPH model not only has better local fit below the knot, but also at the highest quintile.

Table 6: Quintile-Specific NIOSH Cohort Lymphoid Cancer Mortalities Predicted by Cox and Linear Two-Piece Spline Models

Model	Quintile 2	Quintile 3	Quintile 4	Quintile 5
<i>Lymphoid Cancer Deaths Observed in NIOSH Cohort</i>	<i>11</i>	<i>11</i>	<i>11</i>	<i>11</i>
Standard Cox model – 15-yr lag (MLE)	14.4 (8.1, 28.9) ²⁰ (7, 21.8) ²¹	8.0 (4.5, 16.1) (2.4, 13.5)	9.4 (5.2, 18.8) (3.3, 15.4)	9.1 (5.1, 18.3) (3.2, 15.0)
Linear two-piece spline with knot @ 1,600 ppm-days – 15-yr lag (MLE)	20.9 (11.7, 42.0) ²⁰ (11.9, 29.8) ²¹	17.6 (9.8, 35.2) (9.3, 25.8)	20.8 (11.6, 41.7) (11.8, 29.7)	20.9 (11.7, 41.9) (11.9, 29.8)

Note: The TCEQ model accurately predicts the actual cancers for the lowest exposure quintile 2. In contrast, the IRIS model statistically significantly (bold font) over-predicts the actual number of cancers. See TCEQ (2020a, Table 6).

In conclusion, the TCEQ standard CPH model accurately predicts the number of lymphoid deaths observed in the NIOSH study while EPA’s two-piece linear spline model statistically significantly (at the 2.5% significance level) overpredicts the number of lymphoid deaths observed in the NIOSH study. This is true with and without consideration of a reasonably high

²⁰ TCEQ (2020a) used the inverse of the confidence intervals of the SMRs

²¹, for comparison we calculated the CI based on Poisson distribution

HWE of 15% which reasonably accounts for any differences that might exist between the general US population and the NIOSH worker cohort given the absence of a HWE in the NIOSH cohort. This TCEQ “reality check” is a well-accepted approach that is essentially the same approach used by IRIS (2016, Section 4.7) to estimate extra risk for various occupational exposure levels by applying the model to the general population background cancer rates.

7. OEHHA’s reliance on internal analyses and OEHHA’s exclusion of external analysis is based on an oversimplified main conclusion that all external analysis should be ignored because it is confounded by HWE. This is contradicted by the NIOSH study authors’ own published conclusions that “the healthy worker effect would seem an unlikely explanation for the lack of cancer excesses in the exposed versus non-exposed comparisons.” Furthermore, OEHHA’s uncritical acceptance of conclusions of a more recent paper by Park (2020) that there is a Healthy Worker Survival Effect (HWSE) led OEHHA to support EPA IRIS model. However, the conclusions are not supported by the actual results in the paper. Improvements in these and other descriptions of the human epidemiological studies are needed to accurately assess the epidemiological weight-of-evidence.

Pertaining to IUR p. 44

External (comparisons to the general population) and internal analyses (worker to worker comparisons) in occupational epidemiology studies are complementary approaches to the examination of potential exposure-response associations. When they agree, confidence in the presence or absence of risk is enhanced. When they disagree, it is incumbent upon the researchers to explore explanations. In some cases, and more often in the early years of occupational epidemiology, the identification of the potential for the HWE led to a general preference in favor of internal analyses. The HWE, particularly for cancer outcomes, is of much lesser concern in external analyses of cohort studies that have been updated with longer observation periods. The UCC study has had two published updates since the original Greenberg et al. 1990 publication (Teta et al. 1993, Swaen et al., 2009), such that the average follow-up of study subjects has gone from 20 to 37 years. This is what Steenland et al. 2004 was referring to below when he noted the change observed from the original study published in 1991.

“The healthy worker effect has diminished (all-cause mortality was up to an 0.90 from the prior SMR of 0.81) as would be expected with increased follow up.”

ACC’s analysis and explanation of the HWE is also supported by IARC (1999) in its textbook on Cancer Epidemiology: Principles and Methods, which specifically notes that HWE “is known to vary with type of disease, being smaller for cancer than for other major diseases, and it tends to disappear with time since recruitment into the workforce.”

Furthermore, comparisons to worker populations can have their own limitations, such as small sample sizes, baseline risks that suggest they are non-representative of the true low or non-exposed population (e.g., Mikoczy et al., 2011).

OEHHA's complete reliance on internal analyses leads them to consider well-conducted meta-analyses as "flawed" and ignore their conclusions. In general, meta-analysis is a well-accepted method for summarization of results from multiple studies, despite being generally limited to pooled overall risk estimates, as many studies do not provide data by levels of exposure. Furthermore, OEHHA is incorrect in saying that Marsh et al. (2019) did not consider the results of NIOSH internal analyses. In fact, these authors, state:

"However, similar to the LHC results, the NIOSH findings, which revealed no overall excess for breast cancer, were limited to the exposure–response analyses using the log-transformed EtO exposure metric and were questioned by the authors due to their inconsistency across the other EtO metrics considered and potential case over-ascertainment in the higher exposure categories. As discussed above, due to the questionable validity of the positive EtO exposure–response of Mikoczy et al. (2011), these findings add little weight to the overall evidence for EtO exposure and breast cancer."

It is, therefore, scientifically unjustified to ignore the absence of any overall excess of breast cancer in the NIOSH 2004 mortality study and the relevant meta-analyses (Marsh et al. 2019; Vincent et al., 2019).

OEHHA's incomplete evaluations and acceptance of Park, 2020 led them to unequivocally support the EPA model.

Pertaining to IUR p. 43-44

OEHHA states they conducted several qualitative and quantitative assessments of potential bias and errors in the NIOSH study and its use by EPA.

1. Their discussion of exposure assessment is limited to the successful validation NIOSH performed of the post 1978 estimates from their regression model. OEHHA does not consider the NIOSH limitations related to exposure estimates for the pre-1978 period that had no validation, as ACC has previously discussed in detail. Instead, they criticize Bogen et al. (2019) for not validating their estimates. OEHHA cannot simultaneously criticize Bogden, which has contemporaneous material underlying it with respect to pre-1978 exposures and find NIOSH to be of high quality when the author of that study acknowledges that his model incorporates an unsubstantiated assumption that there were no changes in practices that would have reduced worker exposure. As described below, that assumption is manifestly inconsistent with cited literature

2. While OEHHA raises the issues of the HWE and the healthy worker survivor effect (HWSE), they conclude that the internal analyses by NIOSH removed the HWE issue and there is no more than a minor downward OR bias (10% or less), due to the HWSE. They cite Park 2020 to support the existence of a HWSE in the NIOSH data. We agree with OEHHA that neither of these types of biases are relevant. However, any HWE in the NIOSH study has diminished due to extensive follow up, as noted by Steenland, which adds to the relevance of the external analyses of these data. The absence of findings in external analyses of the NIOSH (and UCC data) adds to the uncertainty of the EPA model suggesting a highly potent carcinogen.
3. We also disagree with citing Park (2020) in support of the existence of a HWSE in the NIOSH study, such that control for employment duration leads to a stronger association between cumulative exposure and breast and hematopoietic cancers. In Section 3.2 of Park (2020), the author discusses the findings reported in Table 2. The models include both cumulative exposure to EtO and duration of employment – variables that are very likely highly correlated. For example, if there are two workers doing the same job, one for five years and another for 10, the exposure of the second worker would be double that of the first (absent some significant change in practices).

Park reports “statistically significant negative effect of duration (diminishing rate of leaving with increasing time on job) and positive effects of EtO cumulative exposure that are highly significant for all but the smaller work group of black women (Table 2).” These two variables are in the model used to fit the data with a similar multiplicative role. Given the high correlation between cumulative exposure and duration of employment, a negative coefficient for duration of employment would have to be compensated by a positive coefficient for cumulative exposure. Thus, it is not surprising that a negative coefficient for one variable results in a negative coefficient for the other variable. In fact, in three of the analyses reported in Table 2, the more negative of the coefficient for duration resulted in more positive coefficients for cumulative exposure.

Park (2020) Table 5 shows the results of Park’s models for female breast cancer. There, Park does not find any statistically significant relationship between breast cancer and EtO exposures or employment duration. Park states “For the 102 deaths from female breast cancer, there was no statistically significant difference in mortality on cumulative EtO exposure with a 10-year lag.” Park goes on to indicate that “with 20-year lag, the contribution of cumulative EtO was significant.” It is interesting that although the model is significant, the 95% confidence intervals indicate that the coefficients for cumulative exposures to EtO are not statistically significantly different from zero. That is, the 95% confidence intervals indicate that breast cancer in female workers is not related to cumulative exposure to EtO lagged 20 or 10 years.

Park (2020) Table 6 shows the results for lymphopoietic cancer deaths in the male and female workers. There, Park showed the results for male black workers only because “The 73 lymphopoietic cancer deaths did not represent an overall excess (SMR = 0.96; 95% CI, 0.76-

1.20), based on U.S. rates, particularly for white men (SMR = 0.92), and white women (SMR = 0.85), but among black workers, there was a statistically significant increase in SMR with cumulative EtO exposure (lagged 2.5 years; LRT: P = .011) (Table 6; model 1).” Similar to the results in Table 5 for breast cancer, in Table 6 the models statistically significantly improved the model fit to the lymphohematopoietic deaths in black workers but the coefficients for the cumulative exposure to EtO were not significantly different from zero; that is, there is no statistically significant increasing relationship between lymphopoietic cancer and cumulative exposure to EtO lagged 10 years even in the most sensitive subgroup of workers in the NIOSH study.

The above data are inconsistent with Park’s description of his results in his abstract that were accepted by OEHHA.

4. OEHHA attempted to address the possibility that high intensity- short exposures might explain the NIOSH findings and therefore not be generalizable to the general population, not subject to such types of exposures. Without actual NIOSH data and with incorporation of several questionable assumptions, OEHHA concludes that excluding workers with these exposures from the NIOSH study would have little impact on the EPA exposure-response slope. They assumed that workers with this type of exposure would most likely be in the middle categories of cumulative exposure.

OEHHA then estimated case and control counts in each exposure category, recalculated ORs and exposure-response slopes after excluding various percentages of participants (e.g., 10–30% high intensity-short duration exposed workers) in the middle exposure categories, using guestimates since the actual data were not available. “Exclusions were done at the case/control ratio equal to or slightly lower than that reported in the highest exposure category (where almost all workers probably had at least some high intensity exposure). Overall, these exclusions (with and without replacing the excluded participants into the highest category) had little impact on exposure-response slopes (e.g., 10% or less). This suggests that this issue did not have a major effect on the unit risk calculations or the generalizability of the NIOSH findings.” This conclusion is hardly justified using this obscure analysis and exclusion assumptions, in the absence of actual NIOSH data.

We agree with OEHHA’s summary of the limitations of community-based studies, which makes them inappropriate for exposure-response but disagree that they are useful for hazard assessment.

Pertaining to IUR p. 13, 46

On p.13 OEHHA states, “Four epidemiological studies not included in the US EPA’s IRIS assessment were identified by OEHHA (Garcia et al., 2015; Bulka et al., 2016; Hart et al., 2018; and Jones et al., 2023). These studies investigated associations between residential proximity to EtO-emitting facilities and increased cancer risk. Emissions data were obtained at the community

level from US EPA's TRI (Bulka et al., 2016; Jones et al., 2023; US EPA, 2023a) and National Air Toxics Assessment (Garcia et al., 2015; Hart et al., 2018; US EPA, 2018) databases. While these community-based air pollutant studies can be useful for hazard identification, they were judged by OEHHA to be less useful for dose-response assessment of EtO compared to the occupational studies (Steenland et al., 2003 and 2004; Swaen et al., 2009; and Mikoczy et al., 2011) due to greater uncertainty in estimating individual exposures. This can result in non-differential exposure misclassification, and bias in risk estimates towards the null (Shy et al., 1978). Furthermore, there were lower exposure levels, fewer exposed cases, and potentially less exposure contrast in these community-based studies of EtO, decreasing the sensitivity of the studies to detect an effect.”

We agree with the limitations noted by EPA but disagree that community-based studies are useful for hazard identification of EtO, precisely because of limitations noted in EPA's final sentence. But in addition to concerns about sensitivity (study power), there are serious concerns in such studies related to confounding risks that may be related to potential errors in exposure assessment due to confounding by other sources of EtO exposure, such as smoking and highways. Bias can, therefore, be in either the positive (specificity) or negative direction (sensitivity), making such designs uninformative.

OEHHA fails to discuss the most important limitation of the Mikoczy et al. 2011 study – the questionable comparison group in the internal analyses

Pertaining to IUR p. 16

OEHHA has but one criticism of Mikoczy et al (2011): “Exposures were much lower than in the NIOSH and Union Carbide cohorts, which decreases the ability to detect an effect.” This is apparently OEHHA's explanation for the failure in this study to detect any increase in LH cancers.

While not noted by OEHHA, Mikoczy et al. (2011) has been incorrectly cited in IRIS as supportive of a supralinear association with breast cancer, despite an overall deficit of breast cancer (SIR= 0.81), with or without consideration of a latency period. However, the two higher cumulative exposure groups had statistically significant elevated rates of breast cancer, due to a substantial and statistically significant deficit of breast cancer in the low dose reference group. This deficit is not explained by the HWE, which is primarily related to non-cancer causes and declines with length of follow up. As discussed above, there are clearly advantages to comparing workers to workers in epidemiology studies to overcome possible biases in external comparisons to the general population. However, there may also be disadvantages to using an internal comparison group that may not be recognized. One danger is selecting a referent group that has an unusual deficit of the disease of interest that creates an artifact of an excess as is illustrated in this study, whose referent group breast cancer rates are 50% of general population baseline. This serious limitation was also illuminated in Marsh et al. (2019):

“The validity of the Mikoczy et al. (2011) finding and conclusion can be challenged, however, on the basis of several methodological issues. First, the greater than 2-fold relative excesses in breast cancer incidence risk in the two highest cumulative EO exposure categories were ensured by an inordinately large, statistically significant 48% deficit in breast cancer incidence in the baseline category. The inordinately low baseline SIR for breast cancer is puzzling given that regional rates were used in the external comparisons and that there was no apparent problem with under-ascertainment of breast cancer cases. The healthy worker effect is also not a reasonable explanation for the low baseline breast cancer rate (Gridley et al. 1999). It appears that for unknown reasons, the baseline group used by Mikoczy et al. (2011) differs from the highest two cumulative EO exposure groups on factors other than EO exposure that may be related to breast cancer.”

The IRIS report quantitatively demonstrated the inconsistency of the excesses reported at very low exposures in this population with excesses at only higher exposures in the NIOSH study.

“Thus, crude comparison analyses were done to evaluate whether or not the exposure-response models of the NIOSH study that were used to derive unit risk estimates in this assessment gave predictions consistent with the Mikoczy et al. (2011) internal incidence ratios (IIRs) for the two highest exposure quartiles (see Section J.2.2 of Appendix J). The predicted values for lymphoid cancer were within the 95% CIs for the IIRs for lymphohematopoietic cancer reported by Mikoczy et al. (2011). The predicted values for breast cancer incidence, however, were below the lower limit of the 95% CIs for the IIRs for breast cancer, suggesting that the Mikoczy et al. (2011) results are consistent with a higher unit risk estimate for breast cancer incidence than the one derived in this assessment. The reasons for the discrepancies are unknown... “(IRIS 2016, p.60-61)

Marsh et al. (2019) also addressed this exposure inconsistency:

“Second, cumulative EO exposure levels in the Mikoczy et al. (2011) study were very low relative to both the UCC cohort (Swaen et al. 2009) and NIOSH breast cancer cohort incidence study (Steenland et al. 2003).”

EPA more recently argues that there were substantial exposures in the Mikoczy et al. cohort, making it more comparable to the exposures in the NIOSH cohort, backtracking from the IRIS report. OEHHA reports the breast cancer findings from the internal analysis and ignores the potential bias associated with a non-representative worker comparison group.

8. Based on its acceptance of the IRIS evaluation, OEHHA inaccurately exaggerates the reliability of the NIOSH worker exposure estimates prior to 1978

Pertaining to IUR p. 18, 45

OEHHA could improve the weight of evidence of the epidemiological data by more accurately describing the substantial limitations of the NIOSH worker exposure estimates prior to 1978. Furthermore, NIOSH has lost the electronic files needed to independently assess the NIOSH estimates of exposure prior to 1978 for which NIOSH had no direct measurements²². These data quality issues make open access and independent assessment of the IRIS IUR difficult for lymphoid cancers and impossible for breast cancers.

OEHHA makes the same definitive statement regarding the NIOSH cohort exposure assessment, *“Each participant’s EtO exposure was estimated using a validated multiple regression exposure model that incorporated information on workplace air measurements, sterilization unit size, engineering controls, timing of sterilization, product type, calendar year, and historical process changes.”* (IUR p. 18)

OEHHA also states,

“The NIOSH study was judged by US EPA to be of “high quality” based on the availability of quantitative exposure estimates for individual workers, high-quality exposure assessment, longitudinal study design, large sample size, inclusion of males and females, adequate follow-up, absence of known confounding exposures, multiple study locations, and use of internal comparison groups. The NIOSH study was also reviewed by OEHHA, using the Bradford-Hill guidelines for causal inference and NTP’s risk of bias tool (Hill, 1965; NTP, 2019), and determined to be of high quality and unlikely to be affected by important bias or confounding.” (IUR p. 18)

OEHHA dismisses a robust analysis of the trend of the NIOSH exposure data by Bogen et al. (2019):

“Bogen et al. (2019) have suggested that exposures occurring prior to 1978, the first year that EtO sampling data were available for the NIOSH cohort, may have been dramatically under-predicted by the NIOSH exposure model. However, as noted by these authors, several assumptions were used in their assessment, and the information used to support these assumptions, “were limited in scope and quantitative detail.” In addition, the authors were unable to validate their pre-1978 predictions since no actual worker measurements were available from that time. Overall, because of these and other weaknesses, the accuracy of the Bogen et al. (2019) assessment is unknown to OEHHA.” (IUR, p.44)

²² In response to the panel’s suggestion that the Hornung analysis represents an “invaluable opportunity” for further analysis of the impact of possible errors in exposure estimation, the EPA investigated the possible use of the “errors in variables” approach (page 27 of the panel report). . . Unfortunately, the electronic data files used in the exposure analysis were no longer available, so that analysis based on the errors-in-variables approach was not possible.

These OEHHA statements show, at a minimum, a lack of rigor in evaluating the NIOSH exposure model (Hornung et al. 1994) and its “validation”, and a biased evaluation of the Bogen et al. (2019) paper as discussed in our general comments above.

A more correct statement describing the NIOSH multiple regression exposure model is that the model was only validated for the period 1979-1985 (very few samples were collected from 1976-1978) during which EtO concentration measurements were collected from six facilities, but not for the earlier period of sterilizer facility operations (pre-1978; from late 1930’s to late 1970’s) when a majority of cohort workers were occupationally exposed to EtO and no exposure measurements were collected. An incorrect assumption by Hornung et al. in applying the NIOSH model to the Pre1978 sterilizer operations regarding a key variable “calendar year”, a surrogate for improvement in work practices, inferred no changes in the pre-1978 period and raises serious question about reliability of the NIOSH model in predicting early worker exposures and the dose-response relationship based on the exposures of these early workers in this cohort.

There are several reasons to question the reliability of NIOSH model predictions of early sterilizer worker exposure estimates:

- First, the NIOSH multiple regression exposure model validation (Hornung et al., 1994) was based using a portion of the 1978-1986 to develop the model and another portion of the data to test the model. Therefore, the model was validated for the years with data but not for the early years for which no concentration measurements were available. Hornung et al. provided no other data, information or analyses for sterilizer workers or processes in this earlier time period to check the applicability to this NIOSH exposure model to sterilization workers in the cohort who worked from the late 1930’s to later 1970’s. These facts regarding the NIOSH model validation should have raised concern about model predictions for early sterilization workers.
- Second, Hornung et al. selected Calendar year, a surrogate for improvement in work practices, as the key variable in the NIOSH exposure model to pre-1978 cohort workers. This variable was applied conditionally on the max year 1978 forcing the inverse parabolic fit for years before 1978. This application of calendar year inferred that there were no major changes in work practices in sterilization operations between the late 1930’s and late 1970’s that would have affected worker exposures.

Contrary to this inference, substantial published information and data on early work practices and changes in work practices were found in technical literature, industry documents, and from early workers and industry experts (Bogen et al., 2019). In other words, Bogen et al. (2019) brought far more information and data to inform the validity of the NIOSH model prior to 1978, when NIOSH had insufficient (1976-1978) or no (<1976) data. For example, the numbers of repeated cycles of in chamber, post-exposure vacuum air- or nitrogen washes have increased from two or fewer from early operation up to ten or more for operations in the 1980’s leaving high levels of EtO residues to off

gas in from sterilized materials and packaging from early operations and lower levels in later operations (Goldgraben and Zank 1981; Buonicore et al., 1984).

Consistent with few wash cycles, there are several published studies of rates of EtO off gassing from sterilized materials representing conditions in the 1950's through 1980's (Bruch 1961, 1972; Buonicore et al., 1984; FDA 1978; Stetson et al., 1976; White, 1977). As importantly, early operations stored sterilized materials in the same room as ongoing sterilizer operations where both operational emissions and sterilized material off gassing contributed to worker exposure while later operations moved sterilized material to a separate warehouse room reducing the exposure of highly exposed sterilizer operators (Bogen et al., 2019). Clearly there were important work practice changes over time that need be considered in assessing the exposure of cohort workers.

- Third, the NIOSH exposure model based on the conditioning of calendar year predicted early sterilization workers were exposed to EtO concentration substantially lower than workers in 1978 when exposure concentration predictions were based on measurements (see Figure 8 below from Bogen et al., 2019). One would not expect low exposure concentration when equipment and processes were crude, and little was known about EtO toxicity and no worker protection regulations. The NIOSH model predicted early worker increasing exposure pattern is inconsistent with industrial hygiene data collected in other industries (e.g., on Grote et al., 2003, 2006) and inconsistent with historic worker exposure guidance (ACGIH 1948, 1957) for EtO exposure concentrations in the workplace. ACGIH provided an exposure limit for EtO of 100 ppm in 1948 and 50 ppm in 1957 to encourage reductions in workplace exposure. As a reality check, no ACGIH guidance would have been needed had EtO concentration been as low as predicted by the NIOSH exposure model.
- Fourth, Bogen et al. (2019) performed an engineering/industrial hygiene evaluation of early sterilization worker EtO exposure to assess the reliability of NIOSH exposure model predictions of an increasing exposure trend. Bogen et al. concluded that from the late 1930's to 1978 there was a decreasing exposure trend for sterilizer workers rather than increasing trend from very low exposures to high exposures predicted by the NIOSH exposure model (Figure 8 from Bogen et al., 2019, Figure 5).




Figure 8. Comparison of E/IH (purple lines) and NSR (orange lines) exposure model estimates of occupational respiratory exposures to EtO in facilities that sterilized medical/health products and prevailing ACGIH TLV limits for EtO (dashed lines). Shaded area represents the period during which very limited or (pre-1976) no contemporaneous measurements were available to validate NSR model predictions and during which no EtO-specific regulations were in place to limit occupational EtO exposures. Adapted from Figure 5 of Bogen et al. (2019)

There are no data or analyses available to support OEHHA’s agreement with EPA that the NIOSH model produced a “high-quality exposure assessment.” To the contrary, Bogen et al. (2019) published substantial data and analyses showing that the NIOSH model is flawed and, there was a decreasing rather than increasing EtO exposure trend for pre-1978 sterilizer operators contributing uncertainty to the EPA and OEHHA EtO risk assessments. OEHHA should recognize the limitations of the NIOSH multiple regression exposure model predictions for early sterilizer operators and the potential adverse effects it has on estimation of risk.

Assigning cases with underestimated exposures means that the lymphoid cancer is associated with lower EtO levels than the workers with lymphoid cancers had been exposed to. Underestimating exposures associated with cancers will lead to an overestimation of potency. As there are data on worker exposures to EtO pre-1978 for production workers, it is suggested that OEHHA review production worker cohort monitoring data to ascertain a more reliable picture of early worker exposure patterns. After doing so, OEHHA can further evaluate how to view the NIOSH study in its weight of evidence analysis.

9. The Union Carbide Corp. (UCC) cohort should play a prominent role in considering the strength and consistency of the epidemiology data in supporting the IRIS vs. TCEQ IUR. OEHHA's description of this cohort in the text and Table 7 is missing the internal analysis by Valdez-Flores et al. (2010) which included exploration of different exposure metrics and lag times. The absence of findings in the UCC cohort for male LH is not consistent with a steep slope at low concentrations.

Pertaining to IUR p. 12-13, 16

This UCC study is very important to consider in the weight of evidence because it included long-term follow-up of workers from the 1940s, the infancy in EtO production. The absence of findings in the UCC cohort for male LH is not consistent with a steep slope at low concentrations and does not support the IRIS (2016) derivation of one of the highest IURs. This cohort of 2,174 workers was a subset of another NIOSH study of or more than 29,000 UCC chemical workers in the Kanawha Valley (KV) of WV (Rimsky et al., 1988).

Compared to the NIOSH sterilizer worker mortality study, the UCC study has a smaller cohort sample size but has comparable numbers of LH and lymphoid cancers as those reported in the male component of the NIOSH cohort. The UCC study is, therefore, informative, with respect to males, and the increases in LH and lymphoid cancers reported in the NIOSH study were limited to males (Steenland et al., 2004). Moreover, it is of similar quality to the NIOSH study, especially considering the problems with the NIOSH study noted above.

Furthermore, the quality of the UCC study exposure assessment is comparable to that of the NIOSH study. It employed individual exposure estimates for a substantial period between 1925-1988, utilizing the Greenberg et al. (1990) validated categorization of EtO producing and using departments by level of exposure and quantitative estimates of average intensity by these categories developed by Teta et al. (1993). There were no potential confounders to other chemical exposures because such workers were removed from analysis by Teta et al. (1993), Swaen et al. (2009) and Valdez-Flores et al. (2010).

Exposure data were available for study subjects at the West Virginia (WV) locations starting in 1974. They were available from Union Carbide's Texas City plant that operated identically to the WV location from the early 1960s. This represents an important advantage of the UCC study over the NIOSH study, which had no exposure data prior to 1978 (Bogen et al., 2019; see previous section for detailed discussion). Estimates from EtO operations in the literature were used for the 1940-1956 exposure period, although only a small percentage of the cohort were employed during that period.

Contrary to Table 7 of OEHHA's Draft IUR, there was exploration of log cumulative exposures and multiple lag times. Valdez Flores et al. (2010) reports that Table S11 in Supplemental materials indicates that the fit (maximum likelihood) varies depending upon the exposure scale used in the log cumulative exposure model (i.e., ppm-days, ppm-years, ppb-days, and ppb-

years). Table S11 also illustrates that the Cox proportional hazard model with the slope parameter multiplying cumulative EO exposure fits the data better than any of these four alternative log cumulative exposure models in more than 55% of the combinations of 12 endpoints. None of the other lag periods resulted in a change in statistical significance, therefore no lag was included in the Valdez-Flores et al. (2010) publication. Nevertheless, to be consistent with NIOSH, a lag period of 15 years was applied to the lymphoid analysis by TCEQ (2020a).

In summary, the absence of increases in LH and lymphoid cancers in the UCC study (in both external and/or internal comparisons), as well as the statistically significant increases in the NIOSH study limited to male highest exposure groups in internal comparisons conducted by Steenland et al. (2004), call into question the biological plausibility of the very high IRIS IUR for LH cancers. Overall, the epidemiological evidence does not support EtO as a potent carcinogen with a steep exposure-response pattern at low exposures. The standard CPH model used to derive the TCEQ IUR is a model well-accepted by epidemiologists in cancer exposure-response analysis, is linear at exposure levels of interest, and consistent with an assumption of no-threshold that reflects the epidemiological weight of evidence.

10. The draft IUR document questions the reliability of the Kirman et al. (2021) method of estimating endogenous levels by favoring speculative uncertainty and tangential information on DNA adducts over the toxicokinetic and converging evidence from animals and humans that was presented by Kirman et al. and by data in Filser and Klein (2018). Endogenous levels can greatly exceed the levels to which residents near sterilization facilities may be exposed. While EPA’s potency estimate technically only applies to exposures above endogenous levels, it is questionable that a chemical would be a potent carcinogen at levels that the body produces through natural processes.

Pertaining to IUR p. 29, 30

OEHHA’s Draft IUR indicates that cancer risks account for endogenous levels.

“The EtO exposures from ambient and endogenous sources contribute to HEV levels, other adduct levels, and cumulative cancer risks (i.e., including from other chemicals and conditions). Thus, EtO and ethylene exposures are part of the risk factors accounting for the background cancer risk in the general population, including lymphoid and breast cancers (US EPA, 2016a; 2016b).” (IUR p. 29)

This is a true statement for both the TCEQ and IRIS cancer risk calculation and should not be used as a basis to ignore consideration of endogenous levels as part of an important reality check for derivation of cancer risk specific concentrations. It does not make sense for risk specific concentrations to be orders of magnitude below human endogenous levels, or to be a fraction of the population variability of human endogenous levels.

Most general population background exposure will be endogenous.

Pertaining to IUR p. 29

We applaud OEHHA for including a section on endogenous exposure to EtO. As illustrated by our comments above, this topic is important to future risk assessment and risk management decisions made for EtO.

We recommend to expand this section to include the following:

The biochemical pathways that contribute to endogenous exposures, include: (1) production of ethylene by bacteria normally present in the gastrointestinal tract, which is then absorbed into the body; and (2) systemic production of ethylene by specific precursors and by oxidative stress. Endogenous production of EtO results from the oxidation of ethylene resulting from both sources. These pathways are operable in all mammalian species, with measured EtO biomarker levels (2-hydroxyethyl valine or HEV) generally being higher in laboratory rats and mice than in humans.

Endogenous exposures to EtO are variable. These exposures vary from person to person (interindividual variation) and from day to day (temporal variation), and can be modulated by diet (e.g., fatty acid composition; diet content of precursors that are metabolized to ethylene), medications (e.g., antibiotics), and underlying conditions (e.g., oxidative stress).

Kirman et al. (2021) estimated endogenously produced EtO is the largest contributor to EtO-biomarker levels in general population nonsmokers. The estimated average HEV burden of 29.2 pmol/g Hb resulting from endogenous exposure corresponds to an equivalent median inhalation exposure to 2.3 ppb EtO in air. In this context, EtO RSC exposure (0.0016 ppb) is more than 1000-fold lower than the endogenous exposure and would generally be considered negligible.

Background exogenous exposure is generally a small fraction of total background exposure

Pertaining to IUR p. 29

Most of the general population background exposure arises from endogenous production (~95%), whereas exogenous exposure via inhalation of EtO in ambient air generally constitutes a small fraction (~5%) of total exposure (Kirman et al., 2021). EtO in ambient air has been sampled since 2018 at background monitoring locations across the U.S. under the EPA NATTS and UAT hazardous substances monitoring programs. Samples also have been collected by state agencies and others at local/regional background locations as part of monitoring programs for EtO emitting facilities. Therefore, substantial data exists to characterize general population background exogenous exposures.

Total background exposure from endogenous and exogenous pathways has been characterized from CDC NHANES biomarker data and Kirman et al. (2021) equivalent concentrations

Pertaining to IUR p. 29; NISRL p 18

Our knowledge of EtO background exposure is informed by CDC internal dose data in the form of a representative exposure biomarker, N-(2-hydroxyethyl)-valine (HEV) adduct levels, measured in erythrocytes for nonsmokers and smokers in the U.S. population (CDC 2019; Kirman et al., 2021). HEV adduct levels represent an individual's total background EtO exposure from endogenous and exogenous sources. Kirman et al. 2021 developed a relationship between biomarker (HEV) concentration and total and endogenous equivalent concentrations (equivalent continuous exposure concentrations in ppb) for smokers and nonsmokers in the U.S. population. Endogenous and total equivalent levels reflect air concentrations of EtO that are equivalent to the levels that are produced endogenously, and endogenously and exogenously, respectively. Filser and Klein (2018; Figure 12A) provides an independent PBPK model-based validation of the linear equivalent relationship adopted by Kirman et al. (2021).

OEHHA mischaracterizes the relevance and importance of background endogenous and endogenous equivalent exposure

“While the hemoglobin adducts such as the HEV resulting from endogenous and exogenous EtO may serve as sensitive markers of EtO exposure, the paucity of data on their relationship with the relevant DNA adducts makes it a limiting factor for use in risk assessment (Rietjens et al., 2021[sic]²³).” (IUR p. 30)

- EtO hemoglobin adducts (HEV) are useful biomarkers of exposure, a point also noted in this publication, “...Hb alkylation may serve as a particularly sensitive marker of exposure...” They are used as a cumulative measure of the internal doses of EtO present in blood for several months prior to measurement.
- Kirman’s analysis utilizes HEV to apportion total exposures to EtO from different pathways.
- There are several technical issues associated with measuring EtO based on the best quantifiable DNA adduct (N7-HEG), including high variation across analytical methods, difficulties in sample preparation, uncertainties in repair half-life/depuration rates, and limited data availability, which limit the utility of N7-HEG as a biomarker of exposure.
- Limitations in the understanding in the relationship between HEV and DNA biomarkers does not detract from the utility of HEV biomarkers or from the application in the analysis of Kirman et al. (2021). The “paucity” of data referred to in this comment applies equally to the relationship between external dose measures (e.g., air concentrations) and N7-HEG.

“Alternatively, using the HEV levels to back-calculate endogenous-equivalent air concentrations of EtO is untenable at present as there are no relevant toxicokinetic models or data to support it.” (IUR p. 30)

- Steady state blood levels of EtO (area under the curve or AUC) can be estimated from measured HEV levels with a high degree of confidence since the values for the reaction rate constants for EtO binding to hemoglobin and erythrocyte lifespans are known, as described in Motwani and Tornqvist (2014; see equations 2-3b).
- Although a toxicokinetic model that fully encodes the endogenous formation pathways (Kirman et al. 2021, Figure 4) are not yet available, the model of Filser and Klein (2018) and data cited therein (Figure 12A of Filser and Klein, 2018) are fully consistent with the use of a linear correlation between EtO in air and HEV measurements in humans, as adopted in Kirman et al. (2021) :

²³ OEHA typo. It should be 2022.




Figure 9. Hemoglobin adducts (HEV, nmol/g Hb) in workers exposed to EtO in air (from Filser and Klein, 2018).

- The available worker data depicted in this figure indicate that a linear relationship between HEV adducts and EtO in air is across a broad range of concentrations (~0.1 ppm to ~4 ppm). Furthermore, the PBPK model of Filser and Klein (2018) predict a linear relationship across this range of exposures, as well as for exposures extrapolated below this concentration range (solid black line). Lastly, for exposure levels below the range of worker exposures, the NHANES biomonitoring data in smokers and in non-smokers are also consistent with a linear relationship (depicted by redline; note - log-linear scale) between EtO exposure (using cigarettes per day as a metric) and HEV adduct formation:




Figure 10. Hemoglobin adducts (HEV, pmol/g Hb) in U.S. smokers exposed to EtO in cigarette smoke (NHANES, 2013-16)

- These data indicate that the linear relationship between EtO exposure is maintained from background exposure levels up to 30x background levels. The linear relationship between cigarettes per day and HEV in this figure is consistent with a linear relationship (e.g., assessed by multilinear regression analyses) for another EO biomarker (urinary 2-hydroxyethyl mercapturic acid) as reported by CDC scientist (Kenwood et al., 2021). Together, these data provide evidence to support a linear relationship between HEV and EO exposure as used in Kirman and Hays (2017) and Kirman et al. (2021).

“In this regard, ATSDR (2022) concluded that data are not available to demonstrate that background levels in non-smokers are direct indicators of internal, endogenous EtO exposures.” (IUR p. 30)

- “Direct” measurements of endogenous exposure in isolation are not possible. However, as noted above, indirect estimates of endogenous exposure can be inferred from available data sets (EtO and ET air monitoring; NHANES biomonitoring data).

“The dose-response relationship for endogenous EtO exposures might be different from the dose-responses seen with ambient exposures, possibly sublinear but ultimately unknown (US EPA, 2016a).” (IUR p. 30)

- Measured HEV levels in human populations are dependent upon three parameters: (1) circulating levels of EtO in blood; (2) hemoglobin binding rates; and (3) erythrocyte lifespan. Although there are some possible sources of high-dose nonlinearity (e.g., induction of endogenous production of ethylene by EtO at high doses; theoretical exposure-related effects on erythrocyte turnover due to cytotoxicity) there are no documented sources of low-dose nonlinearity for EtO exposure and HEV formation. Any such nonlinearity would only be relevant at exposures above the range of observation (~0.1 to ~4 ppm) defined by Figure 12A above from Filser and Klein (2018). As noted above, there is no evidence of nonlinearity in the NHANES HEV biomonitoring data as a function of EO exposure (using cigarettes per day).

We believe that there are reliable data for characterizing background endogenous and endogenous equivalent EtO exposure and provide a preface for using background exposure as context for managing and communicating EtO risk.

Kirman et al. (2021) model of external EtO exposures and internal EtO HEV hemoglobin adducts (EtOHEV) is validated in a “forward” analysis as suggested by EPA (2022)

The relationship between NHANES HEV biomonitoring data as a function of EO exposure (using cigarettes per day) established by Kirman and Hays (2017) and Kirman et al. (2021) is validated with a “forward” analysis, as suggested by EPA (2022), based on measured EtO concentrations in mainstream cigarette smoke. Using the linear relationship between external EtO exposures and internal EtO HEV hemoglobin adducts (EtOHEV), Kirman et al. (2021) calculated that an approximate 10-fold increase in general population EtOHEV adducts in smokers compared to non-smokers (CDC NHANES, 2019) was equivalent to a continuous EtO

air exposure of 21.7 ± 20.2 ppb (mean \pm SD). EPA (2022) suggested that the Kirman exposure model could be validated if “forwards determinations of smokers total exposures to EtO” compared reasonably to “backward” estimated EtO exposures derived from the Kirman EOHEV adduct/exposure relationship:

p.69: “EPA also notes that the assumed relationship between HEV adduct measurements and EtO exposures in smokers (Kirman et al. 2017 and 2021) also needs validation. Cigarette smoke contains EtO and ethylene which may be metabolized to EtO. Smokers also experience physiological and biochemical changes that could affect their EtO exposures and/or formation of protein adducts. For validation of the HEV based projections, “forwards” determinations of smokers total exposures to EtO (e.g., as might be assessed using exhaled breath measurements) could be compared with “backwards” calculations of projected EtO exposure levels hypothesized from HEV from adduct level. Paired measurements of breath levels of EtO and ethylene and HEV adduct levels could provide useful bottom-line data to test the HEV/equivalent inhaled concentration hypothesis.”

Importantly, and directly responsive to the EPA-recommended validation exercise, multiple datasets have been published that describe reliable analytically-determined concentrations of EtO in individual cigarettes that can then be converted to total daily EtO smoker exposures dependent on the intensity of smoking behavior (Table 1; Liu et al., 2014; Forster et al., 2018; Jaccard et al., 2019).

Liu et al. (2014) reported for Kentucky Reference 3R4F cigarettes mean concentrations of $8.37 \mu\text{g EtO/cig}$ under the International Organization for Standardization (ISO) smoking regimen and $26.03 \mu\text{g EtO/cig}$ under the “Health Canada intensive” (HCI) smoking regimen. Forster et al. (2018) reported for the updated Kentucky Reference 1R6F cigarettes mean concentrations of $17.2 \mu\text{g EtO/cig}$ (HCI) and $19.3 \mu\text{g EtO/cig}$ (HCI) for Kentucky Reference 3R4F cigarettes. Jaccard et al. (2019) reported for Kentucky Reference 1R6F cigarettes mean concentrations of $5.92 \mu\text{g EtO/cig}$ (ISO) and $17.3 \mu\text{g EtO/cig}$ (HCI). Jaccard et al. (2019) also reported for Kentucky Reference 3R4F cigarettes which yielded mean concentrations of $6.78 \mu\text{g EtO/cig}$ (ISO) and $19.2 \mu\text{g EtO/cig}$ (HCI).

Daily EtO exposure concentrations (EC) can be estimated as $C \times \text{CpD} / \text{IR}$, where C is the reported EtO concentration per cigarette ($\mu\text{g/cig}$), CpD is the number of cigarettes smoked per day (cig/day), and IR is the daily inhalation rate (m^3/day). CpD conservatively assumed to be 17 cig/day based on the average number of cigarette smoked by daily smokers in 2005 as reported by CDC (2018), and IR is assumed to be $16 \text{ m}^3/\text{day}$ based mean inhalation rates for adults aged > 16 yr (EPA 2011). The estimated ECs, shown in Table 7 below, ranged from 3.5 to 15 ppb. These estimates are generally consistent with Kirman et al. (2021) estimates of 21.7 ppb for smokers, 1.9 ppb for non-smokers, which results in 19.8 ppb from smoking contribution, and confirms that HEV adducts can provide reliable estimates of EO exposure.

Table 7. Estimated daily ethylene oxide exposure concentrations based on measured ethylene oxide concentrations in mainstream smoke

Source of EtO Mainstream Smoke Concentration Data	Reference Cigarette	Regimen	Estimated Daily Exposure Concentration (ppb)
Liu et al. 2014	3R4F	ISO	4.98
	3R4F	HCI	15.49
Forster et al. 2018	1R6F	HCI	10.23
	3R4F	HCI	11.48
Jaccard et al. 2019	1R6F	ISO	3.52
	1R6F	HCI	10.29
	3R4F	ISO	4.03
	3R4F	HCI	11.42

The data in Table 7 indicate that the “forward” analytical measurements of EtO in cigarette smoke, when converted to total daily EtO ppm exposures, are in excellent agreement with the “backwards” estimates of the mean and SD measurements of EtO ppm exposure calculated from the high-quality CDC smoker EtOHEV data using the Kirman EtO-EOHEV endogenous-equivalent model approach.

A preliminary analysis of the NHANES HEV data for smokers as a function CpD (see previous figure), demonstrates a linear relationship. The linear slope in this figure (18 pmol/g per average CpD) would correspond exactly with the slope of 10.9 pmol/g per ppb (continuous) if the conversion factor for ppb to CpD is approximately 0.6 ppb per CpD. Using the mean estimated daily concentration from Table 7 (8.9 ± 4.3 ppb) along with the value of 17 CpD, results in an independently derived conversion factor of 0.53 ± 0.25 ppb per CpD. Together these data indicate that the linear correlation between HEV in smoker exposures to EtO is excellent agreement with the linear correlation between HEV and occupational exposures to EtO (i.e., the slope of 10.9 pmol/g per ppb).

The consistency between the “forward” and “backward” smoking-derived EtO exposures can also be used to explore the plausibility of the IRIS IUR as a reasonable predictor of cancer risks associated with low EO exposures. If the IUR is assumed as correct, a 10 ppb (10,000 ppt, as a representative midpoint from Table 7) external EO exposure contributed by smoking is predicted to produce an upper-bound estimate on the order of 1×10^{-2} to 10^{-1} risk of cancers (i.e., the 0.1 ppt 10^{-6} risk projected by IUR), 5 orders of magnitude less than the approximate 10,000 ppt smoking exposures estimated by Kirman et al. (2021) and validated by direct measurement of EtO in cigarettes. This suggests smoking should result in a readily demonstrable cancer signal, but the overall epidemiological data are weak or equivocal for this endpoint. Thus, the smoking data and associated EtO exposure analyses are an important and reliable “reality check” that the IRIS IUR substantially overestimates the low-exposure cancer risks of EtO.

11. OEHHA cites two studies reporting an association between smoking and lymphohematopoietic (LH) cancers published in 2012 (Diver et al. 2012 and Kroll et al., 2012) to discount Kirman et al., (2021) reality checks. These two studies are inconsistent with the lymphoid cancer (NHL, lymphocytic leukemia, multiple myeloma) findings from the NIOSH mortality study (Steenland et al., 2004), upon which IRIS 2016 developed their low exposure high risk model and do not constitute a weight-of-evidence evaluation akin to the Surgeon General report, *The Health Consequences of Smoking —50 Years of Progress*. In addition, OEHHA cites IARC review associating a positive association between tobacco smoking and breast cancer, though not for lymphoid cancer.

Pertaining to IUR p. 29

OEHHA has responded to Kirman et al.'s plausibility argument that, if EtO caused lymphoid tumors, it would be seen in smoker studies, and such an association has not been reported. The draft OEHHA IUR (p. 29) cites two smoker studies, however, published in 2012 (Diver et al. and Kroll et al.) in an attempt to provide biological plausibility for the IRIS cancer risk for lymphoid cancers:

“Since the IARC review, new results from two large prospective cohort studies have found significant associations with lymphoid cancer. The American Cancer Society Cancer Prevention Study II identified 1926 non-Hodgkin lymphoma cases in a cohort of 152,958 men and women (Diver et al., 2012). The study found an association between current smoking and non-Hodgkin lymphoma in women (RR = 1.37, 95% CI = 1.04–1.81), with a positive trend for years smoked ($p < 0.01$). The UK Million Women Study identified 7047 lymphoid cancers in a cohort of 1.3 million women (Kroll et al., 2012). This study found associations between tobacco smoking and Hodgkin lymphoma (1.45 per 10 cigarettes/day, 95% CI = 1.22–1.72) and mature T-cell malignancies (1.38 per 10 cigarettes/day, 95% CI = 1.10–1.73). These large-cohort findings support the plausibility of increased cancer risks from low concentrations of EtO.”

These two studies do not support this statement. They are inconsistent with the lymphoid cancer (NHL, lymphocytic leukemia, multiple myeloma) findings from the NIOSH mortality study (Steenland et al., 2004), upon which IRIS 2016 developed their low exposure high risk model.

Diver et al. is a large cohort study of the relationship between smoking among men and women and the risk for non-Hodgkin lymphoid neoplasms (NHL), a cancer endpoint in IRIS 2016, based on the NIOSH findings for this group of cancers. Diver et al. examined smoking history in detail including status, intensity, duration, cigarettes /day. OEHHA cites Diver et al.'s statistically significant RR for currently smoking women (1.37) but fails to note the deficit in currently smoking males (0.88), the positive trend with cigarettes per day and years smoked for females, no trends for males. This lack of positive association in smoking males occurred despite the fact that males smoked more than females. Furthermore, they fail to note these gender increases are in the opposite direction of the NIOSH gender results associated with EtO exposure, SMRs=1.29

for males and 0.73 for females and the positive slope for males and the negative slope for females in internal analyses.

Given the large number of cases in this study, they were able to demonstrate gender differences statistically. Despite gender differences, they also presented data for males and females combined. A statistically significant trend for NHL was seen for women but no trend for both genders combined. The results for other subtypes of the NIOSH lymphoid category either are positive for females only (lymphocytic leukemia) or non-positive for both genders (multiple myeloma). Diver et al conclude, “In the present study, current smoking was associated with an increased risk of NHL in women but not in men.”

The Kroll et al. (2012) large cohort study was limited to females and examined the relationship between smoking and hematological cancers (both lymphoid and myeloid). OEHHA cites the increased risk observed in this study for **Hodgkin** lymphoma, which is not included in the NIOSH lymphoid category, which includes **non-Hodgkin** lymphoma. So OEHHA cites positive results but for a different disease. The authors do provide RRs for lymphoid cancers in their low exposure smokers (<15 cigarettes per day). No statistically significant increases were seen; no evidence of steep increases at low concentrations.

Both papers summarize the existing literature related to smoking and hematologic cancers as “inconclusive” or “inconsistent”, indicating a need for their research. Based upon their findings, Diver et al., (2012) conclude, “this large cohort study supports an association with cigarette smoking and increased risk of follicular lymphoma in women”, while Kroll et al. (2012) conclude, “Cigarette smoking was associated with increased risk of Hodgkin lymphoma, consistent with previous reports.” The weight of evidence related to smoking and lymphoid tumors (as defined by NIOSH) overall and at low exposure concentrations remain inconsistent and inconclusive.

EPA has also addressed this issue by raising the bar beyond a reality check of the existing literature requiring detailed quantitative analyses with adjustment for confounding and error bounds to rule out an association, ignoring theoretically easy detection of their putative IRIS conclusion of high risk at low exposures.

“As cigarette smoke contains many carcinogens, there is not a reason to expect, that EtO exposures to smokers would contribute a large part of total cancer risks due to cigarette smoking. A quantitative statistical analysis, which has not been reported, would be needed to place bounds on the potential levels of risk from lymphoid and breast cancers in smokers to support comparisons EtO cancer risks. Results from such analyses, appropriately controlled for other risk factors, might support reasonable comparisons of lymphoid and breast cancer rates in smokers and levels of risk of these tumors that would be predicted by EtO exposures from smoking. However, such analyses, to EPA's knowledge, do not appear to have been undertaken” (EPA, 2022, p. 68).

The Agency concedes smokers have elevated EtO exposures “EPA notes that as smokers do have elevated exposures to EtO, further work to define and validate EtO exposure estimates and to

determine statistical bounds on risks for EtO associated cancers in the smokers could in the future contribute important information for EtO risk assessment” (EPA 2022, p. 69).

Neither OEHHA nor EPA considered the published literature showing increased risk of acute myelogenous leukemia (AML) among smokers (IARC, 2012b). The average smoker is exposed to 1.8 mg/day of benzene, which is ten times that of non-smokers (ATSDR, 2007). These findings are plausible and a reasonable reality check, given that benzene is a known cause of AML. Extensive quantitative analyses as described above by EPA is not needed for this purpose, nor would it be needed to question the plausibility of an EtO/lymphoid tumor relationship based on highly exposed smokers.

The citation of these two studies reporting an association between smoking and LH cancers (Diver et al., 2012; Kroll et al., 2012) does not constitute a weight-of-evidence evaluation akin to the Surgeon General report, *The Health Consequences of Smoking —50 Years of Progress* (US DHHS, 2014). More importantly, it does not address the point that an extraordinarily large potency estimate derived by USEPA for EtO is inconsistent with isolated or weak associations. HEV levels in smokers (236 pmol/g Hb; per NHANES) are equivalent to daily exposures to 780 ug/day, which is more than 4 orders of magnitude higher than the NSRL value, which would place predicted cancer risks above 1×10^{-1} . Because smoking prevalence and intensity was much higher in the past, HEV burdens (and predicted risks from EtO exposures) would also be much higher than measured by NHANES. If the unit risk for EtO were truly predictive of its potency, the reported associations between smoking and lymphoid cancers would be larger and more consistently reported across epidemiological studies of smokers.

12. OEHHA’s estimated EtO 10⁻⁵ Risk Specific Concentration (RSC) provide little utility in managing general population risk if background exogenous exposure isn’t considered as an initial reality check. There has been an extensive ambient air measurement campaign over the last several years, including measurements near many EO facilities and at background locations. In many cases, the levels of ethylene oxide far away from facilities are similar to the levels near the facilities.

Pertaining to IUR p. 41; NSRL p. 49, 51

EtO is unique among managed hazardous substances

- Ethylene is emitted to air from natural sources including plants where it functions as a hormone, microbial activity in soils, sediment and plant litter, as well as plants in aquatic systems (reviewed by Sawada and Totsuka 1986; Morgott 2015; Health Canada, 2016). A vast majority of ethylene emissions are from natural sources (Health Canada 2016). Ethylene also is emitted from anthropogenic sources such as biomass burning, including forest fires, and from exhaust emissions from gasoline and diesel vehicles (Swada and Totsuka, 1986; Margott, 2015; Health Canada, 2016). Early reviews also suggested EtO is emitted from vehicle exhaust (EPA 1985) although there is little current published supporting data. As both ethylene and EtO are constituents of tobacco smoke, combustion of tobacco (see Kirman et al., 2021), it seems reasonable that both ethylene and EtO may be emitted by biomass combustion and combustion exhaust from vehicles. As early as the 1970’s, ethylene from natural and unregulated sources was being measured at relatively high levels in urban air (39-700 ppb; Ables and Heggstad, 1973). More recently, EtO has also been measured in ambient air at multiple locations across the U.S. away from known industrial sources to characterize this background exogenous source (median levels 0.03-0.33 ppb; ATSDR 2022; Sheehan et al. 2021; Lewis et al., 2022; Georgia EPD 2022).

Based on the limitations of its risk assessment, OEHHA should consider including discussion of EtO general population background exposure to provide context for risk management and risk communication

OEHHA makes the following statements regarding background exposure,

“Measurements of specific hemoglobin adduct levels, such as N-2-hydroxyethylvaline (HEV), in humans or other species, reflect the integrated exposure to ethylene (endogenous + exogenous) and EtO (endogenous + exogenous). Kirman et al. (2021) showed background exposures to EtO and ethylene in ambient air alone are insufficient to account for HEV levels seen in non-smokers, and endogenous EtO production contributes more to non-smoker HEV levels than ambient EtO and ethylene exposures do. The EtO exposures from ambient and endogenous sources contribute to HEV levels, other adduct levels, and cumulative cancer risks (i.e., including

from other chemicals and conditions). Thus, EtO and ethylene exposures are part of the risk factors accounting for the background cancer risk in the general population, including lymphoid and breast cancers (US EPA, 2016a; 2016b)."

EtO background exposure contributes more to understanding risk than just accounting for background cancer risk; it provides a reality check on managing EtO general population risk when there are unaddressed questions about the representativeness of the risk model. It is likely reasonable to assume that these exposures do not impact the conversions between relative risk and extra risk measures in the dose-response assessment. However, this assumption is not valid for exposures to EtO from smoking, which has changed significantly over time (Kirman et al., 2021) and can vary between worker sub-populations (e.g., salaried vs. hourly workers; Hsu et al., 2019). As such, smoking is a potential confounder for EtO exposures (vs. a confounder to observed cancer response) in the NIOSH cohort. In addition, there is a clear need to include discussion of background exposures for the purposes of risk management and risk communication of total EtO exposures and potential risks. Based on the limitations in the OEHHA EtO risk assessment described above and the unique characteristics of EtO background exposure, a risk management check based on general population background exposure is warranted as a reality check of the utility of OEHHA's assessment RSCs in managing general population EtO risk.

The draft OEHHA assessment estimated EtO RSC provides little utility in managing general population risk if background exogenous exposure isn't considered as an initial reality check

Based on reported monitoring around emitting facilities, the OEHHA 10^{-5} RSC for EtO would be a small fraction of substantially higher ambient background concentrations from natural and unregulated anthropogenic EtO sources otherwise associated with industrial emissions. The EtO IUR document reported ambient background EtO concentrations for the Los Angeles area ranging from 0.02-0.17 ppb. Based on data from the EPA NATTS and UAT monitoring programs for the October 2018 to September 2019 period, ATSDR estimated a national mean background EtO concentration of 0.13 ppb (ATSDR, 2022). Similarly, the same monitoring data for years 2018-2021 showed median (50th percentile) background EtO concentrations ranged from 0.03-0.33 ppb nationally (summarized in Lewis et al., 2022). Local/regional location background EtO concentration for eight sterilization facilities evaluated over an extended period again showed median and 90th percentile background concentrations ranging from 0.07 and 0.26 to 0.13 and 0.56 ppb, respectively (Sheehan et al., 2021).

These data show that background concentrations are variable but more importantly, that everyone nationally (including Californians) is exposed exogenously to mean/median background concentrations of EtO substantially greater (~50-fold) than the EtO RSC. Although it has been suggested that true background concentration based on a refined sampling method (TO 15A) may be lower than measurements based on EPA Method (TO 15), calculations from

recent Georgia EPD background samples by both methods show refined background levels are still substantially greater than the OEHHA RSC.

The OEHHA updated EtO RSC provides little utility in assessing general population risk unless total background exposure from combined exogenous and endogenous contributions are considered as an ultimate reality check

At some monitoring locations, there may be EtO concentrations significantly greater than background concentrations, or modeling may predict risk above RSCs. The total exposure concentration compared to total equivalent background exposure concentration distributions for nonsmokers provides a final reality check of the utility of OEHHA RSC estimates. There are published examples of where total equivalent concentration comparisons have been useful in informing whether further risk mitigation beyond recent emission controls was warranted.

For example, Sheehan et al. (2021) compared 50th and 90th percentile ambient exogenous concentrations from monitoring around eight facilities plus 50th percentile endogenous equivalent concentration (total exposure concentrations) with 50th and 95th percentile total equivalent background concentrations for nonsmokers in the U.S. population and concluded that facility concentrations are contributing negligibly to near residential population total exposure. Similarly, Lewis et al. (2022) compared 5-year average EtO modeled concentrations at near facility residences in Georgia plus background and endogenous concentrations (total exposure) with the 50th 60th and 95th total equivalent concentrations for the nonsmoking U.S. population and again concluded that facility contributions to residential exposure are negligible (see Figure 4 below from Lewis et al. 2022). These total exposure comparisons provide an additional reality check on the health significance of the facility emission contributions to near facility residential EtO exposure.

We suggest that for populations in California living close to emitting facilities, OEHHA consider total equivalent exposure concentrations or the TCEQ RSCs as a final check in managing risk as the proposed OEHHA RSCs have no practical risk management utility.




Figure 11. Estimated total equivalent exposure for the highest 5-year average modeled EtO concentration for all residential receptors by facility ((50th percentile endogenous equivalent for the non-smoking U.S. population, or 2.3 ppb) + (50th percentile background EtO concentration for Georgia, or 0.12 ppb) + (highest 5-year average modeled EtO concentration for all residential receptors by facility)) relative to that of the 50th, 60th, and 95th percentiles of the non-smoking U.S. population (2.5, 2.7, and 5.5 ppb, respectively).

We urge OEHHA to consider these comments and adopt an alternative such as the TCEQ approach. Thank you.

Sincerely,

William Gullledge

William Gullledge

Senior Director

Chemical Products & Technology Division

References

- Ables, F.B. and H.E. Heggestad. 1973. Ethylene: An urban air pollutant, JAPCA 23:6 517-521.
- ACGIH 1948. ACGIH. Documentation of the TLVs and BEIs: Ethylene Oxide; American Conference of Governmental Industrial Hygienists: Cincinnati, OH, USA, 2015.
- ACGIH 1957. ACGIH. Documentation of the TLVs and BEIs: Ethylene Oxide; American Conference of Governmental Industrial Hygienists: Cincinnati, OH, USA, 2015.
- Berman NG, Wong WK, Bhasin S, Ipp E. 1996. Applications of segmented regression models for biomedical studies. *Am J Physiol* 270(4 Pt 1):E723-32
- Bogen, K.T.; Sheehan, P.J.; Valdez-Flores, C.; Li, A.A. 2019. Reevaluation of historical exposures to ethylene oxide among U.S. sterilization workers in the National Institute of Occupational Safety and Health (NIOSH) Study Cohort. *Int. J. Environ. Res. Public Health* 16, 1738.
- Boobis, A. R., Cohen, S. M., Dellarco, V., McGregor, D., Meek, M. E., Vickers, C., Willcocks, D., & Farland, W. 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. *Critical reviews in toxicology*, 36(10), 781–792.
<https://doi.org/10.1080/10408440600977677>
- Bruch, C.W. 1961. Gaseous sterilization. *Ann. Rev. Microbiol.* 15, 245–262.
- Bruch, C.W. 1972. Sterilization of plastics: Toxicity of ethylene oxide residues. In *Industrial Sterilization, Proceedings of the International Symposium, Amsterdam, The Netherlands, 2–4 May 1972*; Phillips, G.B., Miller, W.S., Eds.; Duke University Press: Durham, NC, USA; pp. 49–78.
- Bulka C, Nastoupil LJ, Koff JL, Bernal-Mizrachi L, Ward KC, Williams JN, Bayakly AR, Switchenko JM, Waller LA, Flowers CR. 2016. Relations between residential proximity to EPA-designated toxic release sites and diffuse large B-cell lymphoma incidence. *South Med J.* 109(10):606-614.
- Buonicore, A.J.; Desai, P.R.; Mangone, M.A. 1984. Post Evacuation Cycle Modifications to Reduce Ethylene Oxide Residual Levels and Worker Exposure. Presented at the Medical Device and Diagnostic Industries (MD & DI) East, New York, NY, USA, 14–17; Chemrox Inc.: Bridgeport, CT, USA.
- Burnham KP, Anderson DR. 2002. *Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach*, 2nd ed. Springer-Verlag, New York, NY.
- Diver WR, Patel AV, Thun MJ, Teras LR, and Gapstur SM. 2012. The association between cigarette smoking and non-Hodgkin lymphoid neoplasms in a large US cohort study. *Cancer Causes Control.* 23(8):1231–40. doi: 10.1007/s10552-012-0001-3. Epub 2012 Jun 12.
- Fox AJ, Collier PF. 1976. Low mortality rates in industrial cohort studies due to selection for work and survival in the industry. *Br J Prev Soc Med* 30(4):225-30.

- Filser, J. G., and D. Klein. 2018. A physiologically based toxicokinetic model for inhaled ethylene and ethylene oxide in mouse, rat, and human. *Toxicol. Lett.* 286: 54–79.
- Forster M, Fiebelkorn S, Yurteri C, Mariner D, Liu C, Wright C, McAdam K, Murphy J, Proctor C. 2018. Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. *Regul Toxicol Pharmacol* 93:14-33. doi: 10.1016/j.yrtph.2017.10.006. Epub 2017 Oct 25. PMID: 29080848.
- Garcia E, Hurley S, Nelson DO, Hertz A, Reynolds P. 2015. Hazardous air pollutants and breast cancer risk in California teachers: a cohort study. *Environ Health* 14:14.
- Georgia Environment Protection Division (Georgia EPD). 2022. Ethylene Oxide Monitoring Report. Air Monitoring Branch, May 12, 2022.
- Gkioulekas I, Papageorgiou LG. 2018. Piecewise regression through the Akaike Information Criterion using mathematical programming. *IFAC Papers OnLine* 51-15:730–35.
- Goldgraben, R.; Zank, N. 1981. Mitigation of Worker Exposure to Ethylene Oxide; Report Prepared for the U.S. Environmental Protection Agency; MTR-80 W333; Appendix C-10: Practices Relevant to Worker Exposure at Spice Industry Sites; The Mitre Corp.: McLean, VA, USA, March; pp. C153–C175.
- Gollapudi, B. B., Su, S., Li, A. A., Johnson, G. E., Reiss, R., & R.J. Albertini. 2020. Genotoxicity as a toxicologically relevant endpoint to inform risk assessment: A case study with ethylene oxide. *Environmental and molecular mutagenesis*, 61(9), 852–871. <https://doi.org/10.1002/em.22408>
- Greenberg HL, Ott MG, Shore RE. 1990. Men assigned to ethylene oxide production or other ethylene oxide related chemical manufacturing: a mortality study. *Br J Ind Med* 47(4):221-30.
- Gridley G, Nyren O, Dosemeci M, Moradi T, Adami HO, Carroll L, Zahm SH. 1999. Is there a healthy worker effect for cancer incidence among women in Sweden? *Am J Ind Med.* 36(1):193-9.
- Hamm TE Jr, Guest D, Dent JG. Chronic toxicity and oncogenicity bioassay of inhaled ethylene in Fischer-344 rats. *Fundam Appl Toxicol.* 1984 Jun;4(3 Pt 1):473-8. doi: 10.1016/0272-0590(84)90205-7. PMID: 6745536.
- Hart JE, Bertrand KA, DuPre N, James P, Vieira VM, VoPham T, Mittleman MR, Tamimi RM and Laden F. 2018. Exposure to hazardous air pollutants and risk of incident breast cancer in the Nurses' Health Study II. *Environ Health* 17(1): 28. 10.1186/s12940-018-0372-3.
- Health Canada. 2016. Screening Assessment Ethene (Ethylene) Chemical Abstracts Service Registry Number (CAS RN) 74-85-1; Health Canada: Ontario, CA, USA.
- Hill AB. 1965. The environment and disease: Association or causation? *Proc R Soc Med* 58(5): 295–300.

Hornung, R.W.; Greife, A.L.; Stayner, L.T.; Steenland, N.K.; Herrick, R.F.; Elliott, L.J.; Ringenburt, V.L.; Morawetz, J. 1994. Statistical model for prediction of retrospective exposure to ethylene oxide in an occupational mortality study. *Am. J. Ind. Med.* 25, 825–836.

Hsu, C. D., Momin, F., Hess, J. W., & M. F. de Carvalho. 2019. Trends in Cigarette Smoking Prevalence Among Refinery and Petrochemical Plant Workers, 1950 to 1999. *Journal of occupational and environmental medicine*, 61(12), 989–995.
<https://doi.org/10.1097/JOM.0000000000001714>

International Agency for Research on Cancer (IARC). 1987. *Statistical Methods in Cancer Research. Volume II The design and analysis of cohort studies* by NE Breslow and NE Day. International Agency for Research on Cancer. Lyon, France.

International Agency for Research on Cancer (IARC). 1999. *Cancer Epidemiology: Principles and Methods*. World Health Organization. International Agency for Research on Cancer. Lyon, France.

International Agency for Research on Cancer (IARC). 2012a. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Chemical Agents and Related Occupations. Volume 100F. A Review of Human Carcinogens*. World Health Organization. International Agency for Research on Cancer. Lyon, France.

International Agency for Research on Cancer (IARC). 2012b. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens: Personal Habits and Indoor Combustion. Volume 100E*. World Health Organization. International Agency for Research on Cancer. Lyon, France.

Jaccard G, Djoko DT, Korneliou A, Stabbert R, Belushkin M, Esposito M. 2019. Mainstream smoke constituents and *in vitro* toxicity comparative analysis of 3R4F and 1R6F reference cigarettes. *Toxicol Rep* 6:222-231. doi: 10.1016/j.toxrep.2019.02.009. PMID: 30886823; PMCID: PMC6402302.

Jones RR, Fisher JA, Medgyesi DN, Buller ID, Liao LM, Gierach G, Ward MH and Silverman DT. 2023. Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a U.S. Cohort. *J Natl Cancer Inst.* 10.1093/jnci/djad004.

Kenwood BM, McLoughlin C, Zhang L, Zhu W, Bhandari D, De Jesús VR, Blount BC. 2021. Characterization of the association between cigarette smoking intensity and urinary concentrations of 2-hydroxyethyl mercapturic acid among exclusive cigarette smokers in the National Health and Nutrition Examination Survey (NHANES) 2011-2016. *Biomarkers*. 26(7):656-664. doi: 10.1080/1354750X.2021.1970809. Epub 2021 Sep 2. PMID: 34409911; PMCID: PMC8517914

Kirkeleit J, Riise T, Bjørge T, Christiani DC. 2013. The healthy worker effect in cancer incidence studies. *Am J Epidemiol* 177(11):1218-24.

Kirman, C.R.; Li, A.A.; Sheehan, P.J.; Bus, J.S.; Lewis, R.C.; Hays, S.M. 2021. Ethylene oxide review: Characterization of total exposure via endogenous and exogenous pathways and their

implications to risk assessment and risk management. *J. Toxicol. Environ. Health Part B Crit. Rev.* 24, 1–29.

Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V. 2012. Million Women Study Collaborators. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. *Br J Cancer.* 107(5):879–87. doi: 10.1038/bjc.2012.333. Epub 2012 Aug 9.

Lewis R.C.; Sheehan P.J.; DesAutels C.G. Watson H.N.; Kirman C.R. 2022. Monitored and modeled ambient air concentrations of ethylene oxide: Contextualizing health risk for potentially exposed populations in Georgia. *Int. J. Environ. Res. Public Health* 19, 3364.

Li W, He C, Freudenberg J. 2011. A mathematical framework for examining whether a minimum number of chiasmata is required per metacentric chromosome or chromosome arm in human. *Genomics* 97(3):186-92.

Liu X, Joza P, Masters A, Rickert B. 2014. Determination of Ethylene Oxide (ETO) in Mainstream Cigarette Smoke Using Hydrobromic Acid Derivatization and Gas Chromatography-Mass Spectrometry Method. Presented at 2014 CORESTA Congress, October 12-16, 2014, Québec City, Canada.

Manjanatha MG, Shelton SD, Chen Y, Parsons BL, Myers MB, McKim KL, Gollapudi BB, Moore NP, Haber LT, Allen B, Moore MM. 2017. Dose and Temporal Evaluation of Ethylene Oxide-Induced Mutagenicity in the Lungs of Male Big Blue Mice Following Inhalation Exposure to Carcinogenic Concentrations. *Environ Mol Mutagen* 58:122134.

Marsden DA, Jones DJ, Britton RG, Ognibene T, Ubick E, Johnson GE, Farmer PB, Brown K. 2009. Dose-response relationships for N7-(2-hydroxyethyl)guanine induced by low-dose [¹⁴C]ethylene oxide: evidence for a novel mechanism of endogenous adduct formation. *Cancer Res.* 69(7):3052-9.

Marsh GM, Keeton KA, Riordan AS, Best EA and Benson SM. 2019. Ethylene oxide and risk of lympho-hematopoietic cancer and breast cancer: A systematic literature review and meta-analysis. *Int Arch Occup Environ Health* 92(7): 919–939. 10.1007/s00420-019-01438-z.

Mikoczy Z, Tinnerberg H, Björk J and Albin M. 2011. Cancer incidence and mortality in Swedish sterilant workers exposed to ethylene oxide: Updated cohort study findings 1972–2006. *Int J Environ Res Public Health* 8(6): 2009–2019. 10.3390/ijerph8062009.

Molinari N, Daure J-P, Durand J-F. 2001. Regression splines for threshold selection in survival data analysis. *Statist Med* 20:237–47.

Monson RR. 1986. Observations on the healthy worker effect. *J Occup Med* 28(6):425-33.

Morgott, D.A. 2015. Anthropogenic and biogenic sources of Ethylene and the potential for human exposure: A literature review. *Chem. Biol. Interact.* 241, 10–22.

Motwani HV, Törnqvist M. 2014. In vivo doses of butadiene epoxides as estimated from in vitro enzyme kinetics by using cob(I)alamin and measured hemoglobin adducts: an inter-species

extrapolation approach. *Toxicol Appl Pharmacol.* 281(3):276-84. doi: 10.1016/j.taap.2014.10.011. Epub 2014 Nov 5. PMID: 25448046

National Research Council. 2007. *Models in Environmental Regulatory Decision Making*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/11972>.

National Toxicology Program (NTP). 2019. Risk of Bias Tool. National Toxicology Program (NTP). Updated August 05, 2022. Retrieved October 13, 2021, from <https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/riskbias/index.html>.

Park RM. 2020. Associations between exposure to ethylene oxide, job termination, and cause-specific mortality risk. *Am J Ind Med* 63(7): 577–588. 10.1002/ajim.23115.

Recio L, Donner M, Abernethy D, Pluta L, Steen AM, Wong BA, James A, Preston RJ. 2004. In vivo mutagenicity and mutation spectrum in the bone marrow and testes of B6C3F1 lacI transgenic mice following inhalation exposure to ethylene oxide. *Mutagenesis* 19:215–222.

Rietjens I, Michael A, Bolt HM, Siméon B, Andrea H, Nils H, Christine K, Angela M, Gloria P, Daniel R, Natalie T and Gerhard E. 2022. The role of endogenous versus exogenous sources in the exposome of putative genotoxins and consequences for risk assessment. *Arch Toxicol* 96(5): 1297–1352. 10.1007/s00204-022-03242-0.

Rinsky, R. A., Ott, G., Ward, E., Greenberg, H., Halperin, W., & Leet, T. 1988. Study of mortality among chemical workers in the Kanawha Valley of West Virginia. *American journal of industrial medicine*, 13(4), 429–438. <https://doi.org/10.1002/ajim.4700130403>

Sawada S. and Totsuka T. 1986. Natural and anthropogenic sources and fate of atmospheric ethylene. *Atmos. Environ.* 20 (5), 821-832.

Sheehan, P.J.; Lewis, R.C.; Kirman, C.R.; Watson, H.N.; Winegar, E.D.; Bus, J.S. 2021. Ethylene oxide exposure in U.S. populations residing near sterilization and other industrial facilities: Context based on endogenous and total equivalent concentration exposures. *Int. J. Environ. Res. Public. Health* 18, 607.

Shy CM, Kleinbaum DG, Morgenstern H. 1978. The effect of misclassification of exposure status in epidemiological studies of air pollution health effects. *Bull N Y Acad Med.* 54(11):1155-65.

Steenland K, Whelan E, Deddens J, Stayner L and Ward E. 2003. Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). *Cancer Causes Control* 14(6): 531–539. 10.1023/a:1024891529592.

Steenland K, Stayner L and Deddens J. 2004. Mortality analyses in a cohort of 18235 ethylene oxide exposed workers: Follow up extended from 1987 to 1998. *Occup Environ Med* 61(1): 2–7.

Stetson, J.B.; Whitbourne, J.E.; Eastman, C. 1976. Ethylene oxide degassing of rubber and plastic materials. *Anesthesiol* 44, 174–180.

Swaen GM, Burns C, Teta JM, Bodner K, Keenan D and Bodnar CM. 2009. Mortality study update of ethylene oxide workers in chemical manufacturing: A 15 year update. *J Occup Environ Med* 51(6): 714–723. 10.1097/JOM.0b013e3181a2ca20.

Swenberg JA, Fryar-Tita E, Jeong YC, Boysen G, Starr T, Walker VE, Albertini RJ. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. *Chem Res Toxicol*. 2008 Jan;21(1):253-65. doi: 10.1021/tx700408t. Epub 2007 Dec 28. PMID: 18161944. Teta MJ, Benson LO, Vitale JN. 1993. Mortality study of EO workers in chemical manufacturing: a 10 year update. *Br J Ind Med* 50(8):704-9.

Texas Commission on Environmental Quality (TCEQ). 2015. TCEQ Guidelines to Develop Toxicity Factors. RG-442. Texas Commission on Environmental Quality (TCEQ). https://www.tceq.texas.gov/assets/public/comm_exec/pubs/rg/rg-442.pdf.

Texas Commission on Environmental Quality (TCEQ). 2020a. Ethylene Oxide Carcinogenic Dose-Response Assessment, CAS Registry Number: 75-21-8. Texas Commission on Environmental Quality (TCEQ). <https://www.tceq.texas.gov/toxicology/ethylene-oxide>

Texas Commission on Environmental Quality (TCEQ). 2020b. Response to External Peer Review Comments Received on the Ethylene Oxide Development Support Document, CAS Registry Number: 75-21-8. Texas Commission on Environmental Quality (TCEQ). <https://www.tceq.texas.gov/downloads/toxicology/dsd/comments/eto-rtc-peer-review.pdf>

U.S. Agency for Toxic Substances and Disease Registry (ATSDR). 2007. Toxicological Profile for Benzene. United States Department of Health and Human Services. Agency for Toxic Substances and Disease Registry (ATSDR). <https://www.atsdr.cdc.gov/ToxProfiles/tp3.pdf>.

U.S. Agency for Toxic Substances and Disease Registry (ATSDR). 2022. Toxicological Profile for Ethylene Oxide. United States Department of Health and Human Services. Agency for Toxic Substances and Disease Registry (ATSDR). <https://www.atsdr.cdc.gov/toxprofiles/tp137.pdf>.

U.S. Centers for Disease Control and Prevention (CDC). 2018. Smoking is down, but almost 38 million American adults still smoke. <https://www.cdc.gov/media/releases/2018/p0118-smoking-rates-declining.htm>.

U.S. Centers for Disease Control and Prevention (CDC). 2019. National Report on Human Exposure to Environmental Chemicals: Ethylene Oxide Hemoglobin Adducts. U.S. Centers for Disease Control and Prevention. Available online: <https://www.cdc.gov/exposurereport/index.html> (accessed on 31 January 2019).

U.S. Department of Health and Human Services (US DHHS). 2014. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.

U.S. Environmental Protection Agency (EPA). 1985. Health Assessment Document for Ethylene Oxide. United States Environmental Protection Agency, Office of Health and Environmental Assessment, EPA 600/8-84/009F.

U.S. Environmental Protection Agency (EPA). 2005. Guidelines for Carcinogen Risk Assessment. United States Environmental Protection Agency, Risk Assessment Forum, Washington, DC.

U.S. Environmental Protection Agency (EPA). 2011. Exposure Factors Handbook: 2011 Edition. United States Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment. Washington, DC.

U.S. Environmental Protection Agency (EPA). 2016a. Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide (CASRN 75-21-8): In Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635/R-16/350Fa. United States Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment. Washington, DC. Retrieved August 12, 2022, from https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=329730

U.S. Environmental Protection Agency (EPA). 2016b. Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide: Appendices (CASRN 75-21-8). In Support of Summary Information on the Integrated Risk Information System (IRIS). United States Environmental Protection Agency (US EPA). https://cfpub.epa.gov/si/si_public_file_download.cfm?p_download_id=529971&Lab=NCEA.

U.S. Environmental Protection Agency (EPA). 2018. National Air Toxics Assessment. United States Environmental Protection Agency. Retrieved February 22, 2023, from <https://www.epa.gov/national-air-toxics-assessment>

U.S. Environmental Protection Agency (EPA). 2022. Summary of Public Comments and Responses for the Reconsideration of the 2020 National Emission Standards for Hazardous Air Pollutants: Miscellaneous Organic Chemical Manufacturing Residual Risk and Technology Review. U. S. Environmental Protection Agency, Office of Air Quality Planning and Standards, Sector Policies and Programs Division (E-143-01), Research Triangle Park, North Carolina 27711.

U.S. Environmental Protection Agency (EPA). 2023. Toxics Release Inventory (TRI) Program. United States Environmental Protection Agency. Retrieved February 22, 2023, from <https://www.epa.gov/toxics-release-inventory-tri-program>

U.S. Food and Drug Administration (FDA). 1978. Ethylene Oxide, Ethylene Chlorohydrin, and Ethylene Glycol: Proposed Maximum Residue Limits and Maximum Levels of Exposure; 43 FR 27474; Food and Drug Administration: Washington, DC, USA, 1978.

Valdez-Flores C, Sielken RL Jr. 2013. Misinterpretation of categorical rate ratios and inappropriate exposure-response model fitting can lead to biased estimates of risk: ethylene oxide case study. *Regul Toxicol Pharmacol* 67(2):206-14.

Valdez-Flores C, Sielken RL, Teta MJ. 2010. Quantitative cancer risk assessment based on NIOSH and UCC epidemiological data for workers exposed to ethylene oxide. *Regul Toxicol Pharmacol* 56:2010 312-320.

Vergnes JS, Pritts IM. Effects of ethylene on micronucleus formation in the bone marrow of rats and mice following four weeks of inhalation exposure. *Mutat Res.* 1994 Jul;324(3):87-91. doi: 10.1016/0165-7992(94)90051-5. PMID: 7517513.

Vincent MJ, Kozal JS, Thompson WJ, Maier A, Dotson GS, Best EA and Mundt KA. 2019. Ethylene oxide: Cancer evidence integration and dose-response implications. *Dose Response* 17(4): 1559325819888317. 10.1177/1559325819888317.

<https://journals.sagepub.com/doi/pdf/10.1177/1559325819888317>

Von Grote, J.; Hürlimann, C.; Scheringer, M.; Hungerbühler, K. 2003. Reduction of occupational exposure to perchloroethylene and trichloroethylene in metal degreasing over the last 30 years: Influences of technology innovation and legislation. *J. Expo. Anal. Environ. Epidemiol.* 13, 325–340.

Von Grote, J.; Hürlimann, C.; Scheringer, M.; Hunger, K. 2006. Assessing occupational exposure to perchloroethylene in dry cleaning. *J. Occup. Environ. Hyg.* 3, 606–619.

Walker VE, Fennell TR, Upton PB, Skopek TR, Prevost V, Shuker DE, Swenberg JA. 1992. Molecular dosimetry of ethylene oxide: formation and persistence of 7-(2-hydroxyethyl)guanine in DNA following repeated exposures of rats and mice. *Cancer Res.* 52(16):4328-34. PMID: 1643630.

Walker VE, Wu KY, Upton PB, Ranasinghe A, Scheller N, Cho MH, Vergnes JS, Skopek TR, Swenberg JA. Biomarkers of exposure and effect as indicators of potential carcinogenic risk arising from in vivo metabolism of ethylene to ethylene oxide. *Carcinogenesis.* 2000 Sep;21(9):1661-9. doi: 10.1093/carcin/21.9.1661. PMID: 10964097.

White, J.D. 1977. Standard aeration for gas-sterilized plastics. *J. Hyg.* 79, 225–232.

Zeljezic D, Mladinic M, Kopjar N and Radulovic AH. 2016. Evaluation of genome damage in subjects occupationally exposed to possible carcinogens. *Toxicol Ind Health* 32(9): 1570–1580. 10.1177/0748233714568478.

APPENDIX B

January 26, 2024, ACC Comments on Draft Cancer Inhalation
Unit Risk Factor (IUR) for Ethylene Oxide submitted to Scientific
Review Panel on Toxic Air Contaminants



January 26, 2024

Submitted via California ARB Comments Portal

California Air Resources Board
Scientific Review Panel on Toxic Air Contaminants
1001 I Street
Sacramento, California 95812

Re: ACC Comments on Draft Cancer Inhalation Unit Risk Factor (IUR) for Ethylene Oxide

Members of the Scientific Review Panel:

The Ethylene Oxide Panel (EO Panel) of the American Chemistry Council (ACC) appreciates the opportunity to provide comments to the Scientific Review Panel (SRP) on OEHHA's proposed Cancer Inhalation Unit Risk Factor for ethylene oxide (EtO) and its accompanying Draft Technical Support Document (Draft IUR, 2023). The EO Panel includes the major producers and users of EO in North America.

These comments highlight key points related to the dose-response modeling and breast cancer that are discussed in greater detail in the attached ACC detailed comments on the Draft IUR that were submitted to OEHHA. As part of this review, we urge OEHHA to seriously consider our comments together with the more detailed ACC comments that address OEHHA's new analysis and evaluations. The attached ACC comments and slide presentation provide additional references and analysis supporting the following key points that summarize why dose-response analysis using a single log-linear CPH model has greater biological plausibility and is more consistent with the observed epidemiology data:

- The USEPA's 2-slope model is comprised of a steep slope in the low-dose region with high-dose plateau. This appears to be an artifact of embedded decisions made in the modeling, in particular:
 - o Combining men's & women's data exhibiting dramatically different exposure- response behaviors
 - o Incorrect statistics, misleading visual fit comparisons, over-reliance on biologically implausible log-cumulative models
- A steep slope in the low dose region is inconsistent with the epidemiology data.

- o Signals for LH, lymphoid and breast cancer are weak and inconsistent across available studies.
- A steep slope in the low-dose-region is inconsistent with the biological evidence
 - o Genotoxicity for EtO do not exhibit this behavior.
 - o EtO toxicokinetics do not exhibit the behavior of the EPA's steep initial slope.
 - o The carcinogenicity data for ethylene and EtO do not exhibit this behavior.
- EPA's 2-slope model overpredicts risk
 - o Overestimating cases in the range of observation.
 - o The resulting IUR predicts unacceptable excess risk in ambient air, exhaled air and fruits
 - o As such, the use of USEPA's IUR to assess, manage, and communicate risks from EtO is not recommended.
- The log-linear CPH model as performed by TCEQ is preferred
 - o Accurately predicts the number of cancer cases in range of observation for the NIOSH cohort.
 - o Is approximately linear in the low-dose range without exhibiting a plateau that is inconsistent with relevant mechanistic data.
 - o Is a standard model used for epidemiology and is more representative of the epidemiological weight of evidence.
 - o The behavior is consistent with the underlying genotoxicity, carcinogenicity and toxicokinetics of EtO.

We urge OEHHA to consider these comments and adopt an alternative such as the TCEQ approach. Thank you.

Sincerely,

William Gulledge

William Gulledge

Senior Director

Chemical Products & Technology Division

Attachments:

1. Comments to the California Air Resources Board Scientific Review Panel on Toxic Air Contaminants on the Draft OEHHA Inhalation Unit Risk, January 26, 2024
2. ACC Comments on Draft Cancer Inhalation Unit Risk Factor for Ethylene Oxide, June 14, 2023
3. American Chemistry Council Ethylene Oxide Panel Comments on the OEHHA Draft IUR, July 14, 2023

COMMENTS TO THE CALIFORNIA AIR RESOURCES BOARD SCIENTIFIC REVIEW PANEL (SRP) ON TOXIC AIR CONTAMINANTS ON THE DRAFT OEHHA INHALATION UNIT RISK¹

Jane Teta², Bhaskar Gollapudi³, Kenneth T. Bogen⁴, Steave Su², James Bus⁵, Abby Li⁶

We appreciate the opportunity to provide comments to the California Air Resources Board Scientific Review Panel (SRP) regarding OEHHA's proposed Cancer Inhalation Unit Risk (IUR) Factor for ethylene oxide (EtO) and its accompanying Draft Technical Support Document (Draft IUR, 2023). These comments highlight key points related to the dose-response modeling and breast cancer that are discussed in greater detail in the attached American Chemistry Council (ACC) detailed comments on the Draft IUR that were submitted to OEHHA.

As reviewed by the Draft IUR, there are currently two government agency risk assessments for EtO, one conducted by USEPA and the other by TCEQ. Both TCEQ's and EPA's risk assessments are based on analyses of the same occupational cohort exposed to EtO. OEHHA's Draft IUR is based on the USEPA risk assessment. The principal endpoint of interest in both risk assessments is lymphoid cancer mortalities. TCEQ focuses solely on lymphoid cancers. EPA includes both breast and lymphoid cancers, but lymphoid cancer is the major contributor to the EPA IUR. Both use the Cox proportional hazards (CPH) modeling approach as the main statistical tool and cumulative exposure (ppm-days) to EtO as the metric of exposure. For the TCEQ model, the mathematical form of the CPH model is a single slope log-linear model, which approaches linearity at the lower exposures. In contrast, OEHHA and USEPA use two linear CPH models joined by a knot (inflection point) such that the first slope is much steeper than the second.

It is very clear that the OEHHA team put in a tremendous amount of effort to evaluate and clearly summarize the EtO epidemiology and animal toxicity studies. However, for the dose-response assessment, OEHHA relied heavily on the IRIS assessment due to the lack of access to the NIOSH data. The Draft IUR modeled "the categorical data", but these are 5 grouped estimates of the actual individual data including 53 cases of lymphoid mortalities. In fact, the EPA Science Advisory Board (SAB, 2015) recommended that EPA should re-do its modeling based on individual results instead of modeling the 5 categorical estimates (quintiles) as was proposed in the draft IRIS assessment. Yet, in the final IRIS assessment EPA graphically presents these quintiles as point estimates to visually determine which model fits the best. In essence, the IRIS assessment uses the very estimates EPA SAB considered to be not representative of the individual data to determine which continuous model of the individual data

¹ This white paper was funded by the American Chemistry Council

² Exponent, Inc. New York, NY.

³ Toxicology Consultant, Midland, MI

⁴ Versar Global Solutions through Exponent, Inc Oakland, CA


⁵ Exponent, Inc. Alexandria, VA

⁶ Exponent, Inc. Oakland, CA

to select from. While categorical models with a small number of odds ratios can be useful for identifying possible associations, they do not identify the shape of the dose-response curve based on continuous data modeling of as shown in detail by Valdez-Flores and Sielken (2013).

The EPA IRIS figures that the Draft IUR relies on to evaluate model-fit are not fit for this purpose. First, the figures do not convey the actual data that were fit. Second, they give the false impression that TCEQ’s model “underestimates” the categorical RR estimates. This problem is best illustrated by public comments to TCEQ, which presented the following graph and incorrectly stated that the CPH model “underestimates” the categorical relative rate (RR) estimates (TCEQ response to public comments p. 41) based on visual fit comparisons. The reproduction of this graph in this public comment failed to include the easily missed footnote included in all EPA figures of RR correctly warning that the different models have different implicitly estimate baseline risks; thus, they are not strictly comparable to each other along the y-axis.

Figure 1. Figure from Public Comments to TCEQ (2020)



Reproduction of Figure 4-3 from EPA assessment, with black rectangles and text added to highlight TCEQ’s model, the categorical RR estimates, and EPA’s selected model.⁵⁴

The Draft IUR (p.36) makes the same visual comparison error by stating “Other models, including the log-linear models (e.g., Cox regression) and the models using categorical data or exposure transformations, generally resulted in sloped that appeared to dramatically over- or under-predict the actual study results, especially in the lower-exposure ranges”. In contrast, the ground-truthing approach used by TCEQ comparing expected and observed numbers of lymphoid cancers in the NIOSH and UCC cohorts comports with traditional well-accepted statistical practice (discussed in further detail below and in ACC detailed comments).

While the Draft IUR admirably attempts to conduct an “independent” evaluation of bias in EPA’s model and the NIOSH epidemiological data, these efforts are based on assumptions in the absence of access to the actual data and repeats EPA’s focus on categorical grouped estimates that are not the data modeled. ACC had access to the NIOSH exposure and mortality data prior to 2016, and our comments are based on our analysis of these individual data.

Recently, in response to public comments on new proposed EtO regulations, EPA has increasingly relied on the aforementioned misleading visual fit comparisons with grouped estimates as the basis for justifying a 2-piece spline model. EPA acknowledges that two statistical expert peer-reviewers for the TCEQ assessment agree that the EPA IRIS incorrectly calculated the p-values for likelihood-ratio tests of model-fit adequacy. With TCEQ’s correction, neither the TCEQ model nor the EPA’s model exhibit a statistically adequate fit by EPA’s own stated criteria ($p < 0.10$, EPA IRIS p.4-20).

It is relevant to consider here that the original NIOSH lymphoid study applied a large number of curve-fitting models (>50 for each cancer) in an exploratory statistical modeling exercise that included 5 different exposure metrics, 5 different lags for each exposure metric, males alone, females alone (Steenland et al. 2004). The authors reported only 3 continuous models with specific lags to be statistically significant, all of which are log cumulative CPH models, which EPA considers to be biologically implausible. Importantly, the NIOSH study authors concluded that male and female workers in the **highest** cumulative exposures and longest latency had statistically significant excesses for lymphoid cancer mortality (males) and the fully ascertained breast cancer mortality (females), respectively (Steenland et al. 2004).

While statistics provide an important objective method for assessing model-fit adequacy, the ACC comments emphasize the holistic integration of the epidemiological and biological evidence in the selection of a dose-response model. EPA has argued that if the statistics for the model fits are comparable, then why not select the most protective one? We disagree, and so does EPA SAB. EPA SAB (2015) stated that “Any model that is to be considered reasonable for risk assessment must have a dose-response form that is both biologically plausible and consistent with the observed data.” While EPA may try to invoke the more protective option, that approach is valid only if the models are statistically significant **and biologically plausible**. In the case of lymphoid cancers, neither the TCEQ nor the EPA models indicates a significant relationship between EtO exposure and lymphoid cancers. More importantly, the TCEQ model is more consistent with the observed epidemiologic data and the genotoxicity data most relevant for lymphoid cancers.

The OEHHA Draft IUR states that US EPA concluded that the EPA 2-piece spline model provides the best biologically plausible fit to underlying NIOSH study data, especially in the lower exposure region. The Draft IUR also quotes EPA as stating that model selection weighs statistical and biological consideration. However, careful examination of the IRIS assessment indicates that EPA only considered biological plausibility in the two following respects:

1. when rejecting the statistically significant but implausibly steep log cumulative model
2. when justifying moving the knot of the EPA's favored model.

In both cases, EPA did not provide any biological evidence other than to state that it is biologically implausible for the dose-response to be so steep, and its IRIS assessment provides no explanation except merely to declare that the log cumulative and the initially selected knot these two cases are biologically implausible. We agree with EPA that the log cumulative models and the 2-piece spline model with the statistical best-fitting (100-ppm-days) knot are biologically implausible based on the NIOSH study alone, the epidemiological weight of evidence, the most relevant genotoxicity data, the carcinogenicity data and the toxicokinetic properties of EtO (see detailed ACC comments). But these same reasons support the TCEQ's standard (log-linear) Cox Proportional Hazards model over the EPA IRIS 2-piece spline model with knot at 1600 ppm-years. After rejecting the log-cumulative model, EPA then resurrects the biologically implausible log cumulative model to provide a statistical rationale for selecting the EPA IRIS model based on a flawed visual fit comparison with categorical estimates, which are not the data modeled.

Consistency with the Observed Data

The IRIS assessment for EtO is based on the 2-piece spline model with a steep increasing risk at low exposures, implying that EtO is a potent carcinogen. The NIOSH study of over 17,000 sterilant workers, the UCC study of over 2000 chemical workers from the 1930s, and the large number of other occupational cohort studies over a 40 yr. period do not support this implication.

There is no significant overall excess of lymphoid cancer mortality or of breast cancer incidence or mortality in the NIOSH studies, when compared to the general population. These findings cannot be attributed to the Healthy Worker Effect (HWE) as this study population has had extensive follow up known to diminish the HWE. The NIOSH authors also clearly dismiss the existence of a HWE for this study group. Their conclusions are consistent with that of the International Agency for Research on Cancer textbook on Cancer Epidemiology: Principles and Methods (IARC, 1999), which specifically notes that HWE "is known to vary with type of disease, being smaller for cancer than for other major diseases, and it tends to disappear with time since recruitment into the workforce." In worker-to-worker comparisons, increased lymphoid cancer mortality was observed in the NIOSH study, for males only, in only the highest exposure group with a 15-year lag. A statistically significant excess was observed for breast cancer mortality, again only in the highest exposure category with a 20-year lag. Neither corresponding overall trend exhibits both fit-adequacy and better fit than a corresponding CPH (i.e., approximately linear) fit.

The conclusions of the NIOSH authors with respect to the findings of their mortality study were very tempered.

“Positive-exposure response trends were found for males only. Reasons for the sex specificity of this effect are not known. There was also some evidence of a positive exposure-response for breast cancer mortality.”

The positive breast cancer incidence findings from worker-to-worker comparisons were also cautiously interpreted by the NIOSH authors who stated:

“Our data suggest that EtO is associated with breast cancer, but a causal interpretation is weakened due to some inconsistencies in exposure-response trends and possible biases due to non-response and incomplete cancer ascertainment.”

In any study of this type, in which multiple disease endpoints are considered and a multiplicity of models examined, there are the very real problems of multiple comparisons and data dredging, particularly when there is no consistency of findings within subgroups in the study. Although the authors argue that their study is exempt from these problems, the Steenland et al. (2004) study is no exception as described above. There appears to be no biological explanation for the discrepant findings for lymphoid cancer between males and females nor for the discrepant results between the NIOSH and UCC cohorts. A more defensible conclusion would be that this study generated hypotheses to be tested in future studies. Therefore, a more nuanced conclusion, based on the NIOSH study, is that evidence for a causal association between exposure EtO and any cancer in humans is weak and does not support a steeper exposure response model at lower exposures compared to higher exposures. The standard CPH dose-response model is more consistent with the observed epidemiology data.

Biological Plausibility

There are no in vitro or in vivo data specific to EtO that support the EPA spline-model assumption that risk of EtO-induced genotoxicity, mutations, or cancer increases sharply in relation to cumulative EtO exposure and then markedly saturates at relatively low levels of cumulative EtO exposure. To the contrary, mechanistic data indicate that DNA-damage-related EtO endpoints are expected to exhibit a linear, monotonic, no-threshold dose-response without any marked inflection point(s) in relation to exposure at relatively low exposure levels. Particularly in view of lack of any statistical evidence of improved data fit compared to traditional linear risk extrapolation, spline-model risk extrapolation is neither biologically nor statistically warranted. For the purpose of these overarching comments, we focus on the mutagenicity evidence, which was reviewed in the Draft IUR, but not considered with respect to the biological plausibility of model selection to apply to the NIOSH study.

There is little disagreement that mutagenicity is the presumed mode of action (MoA) through which EtO contributes to its carcinogenicity. Currently, there is no other alternate cancer MoA to exclude mutagenicity. EtO is a direct alkylating agent, meaning that it does not require any

metabolic conversion to become reactive with DNA. On the other hand, metabolic processes such as conjugation with GSH or hydrolysis through epoxide hydrolase are involved in the efficient detoxification of EtO at lower exposure levels. Accordingly, it is expected that overwhelming detoxification plays an important role in EtO induced DNA reactivity.

Reaction of EtO with DNA leads to the formation of various types of DNA adducts and some types of adducts contribute to the formation of mutations. In this context, it is important to mention that there are cellular repair processes that can effectively deal with the DNA damage at low doses, and it is only at doses that saturate these repair process that one should expect the unrepaired adducts leading to mutagenicity.

There is an extensive body of literature investigating the mutagenicity of EtO. EtO has been shown to be mutagenic both in vitro and in vivo test systems. From this perspective, one may conclude that the evidence for EtO's mutagenicity is strong. This does not mean that the mutagenic potency of EtO is strong. To the contrary, EtO is a weak mutagen, meaning that it requires relatively high doses and long exposure durations to elicit its mutagenic activity. The cellular detoxification and DNA repair processes coupled with its inability to bioaccumulate play a critical role in the weak mutagenicity of EtO. For a direct acting mutagen like EtO, the worst-case dose-response scenario for mutagenicity is linear with a single slope, no thresholds, and no inflection points at relatively low levels of cumulative exposure. For EtO, however, a more plausible dose-response is to have a shallow slope at lower doses and a steeper slope at higher doses due to dose-disproportionate increase in internal dose because of the saturation of detoxification processes and/or overwhelming of DNA repair processes. Multiple lines of experimental evidence support a shallower initial slope for the EtO-induced dose-response. For DNA adducts, the molecular initiating event for EtO-induced mutagenicity/carcinogenicity, Marsden et al. (2009) using one of the most sensitive analytical tools demonstrated little increase in DNA adduct formation in the livers of rats intraperitoneally injected with lower dose levels of EtO. Thus, even if we don't believe there are thresholds, these data at best conservatively demonstrate that the DNA adduct formation has a linear response with a single slope over the entire range of historical occupational exposures examined.

Further experimental evidence for the weak mutagenicity and shallower dose-response for EtO comes from the bone marrow (Recio et al., 2004) and lung (Manjanatha et al., 2017) tissues of Big Blue transgenic mice exposed to EtO. These two tissues are highly relevant to tumor findings in EtO-exposed mice. In both cases, the shape of the dose response is at best conservatively characterized as having a single linear slope. In fact, significant increases in mutations were observed only at the higher doses of EtO (i.e., 100 ppm and higher in the bone marrow and at 200 ppm in the lung) and that too after extended durations of exposure (i.e., after 48 weeks but not at 12 or 24 weeks in the bone marrow and at 8 but not 4 weeks in the lung). These data demonstrate that EtO is a relatively weak mutagen and the shape of the dose-response curve is conservatively linear with a single slope, but more likely with a shallower slope at relatively lower dose levels.

In the most recent EPA (2022) response to public comments regarding the lack of consideration of the biological evidence in the dose-response assessment, EPA conducted a highly subjective visual inspection of genotoxicity data to support their claim that the biological evidence cannot be used to inform biological plausibility. The EPA (2022) evaluation involved (a) plotting the data as point estimates without error bars, (b) drawing a straight line between the response levels for the lowest and highest dose levels, and (c) declaring the dose-response to be supralinear or sublinear depending on whether the responses for the mid-dose levels visually appeared to be above or below the line. This visual inspection did not involve any consideration of validly assessed statistical significance or evaluation of which data set and dose regimen is most relevant and useful to inform epidemiology data based on cumulative exposures. In their response to public comments, EPA opined that dose-response information obtained from animal genotoxicity studies would not allow selection of dose response models for human risk assessment for EtO. This position seems to be at odds with the agency's 2005 Cancer Guidelines stating that "[i]f dose-response analysis of nontumor key events is more informative about the carcinogenic process for an agent, it can be used in lieu of, or in conjunction with, tumor incidence analysis for the overall dose-response assessment." Thus, properly modeled genotoxicity dose-response information from animal studies should be considered in the selection of the model for EtO risk assessment.

Figure 2: EtO-induced Dose-Response for DNA Adduct Formation (Marsden et al., 2009).




Figure 3: Dose-Response for the Induction of *lac I* Mutations in Big Blue Mouse Bone Marrow (Recio et al., 2004).





Figure 4: Dose-Response for the induction of *cII* Mutations in Big Blue Lung Tissue (Manjanatha et al., 2017).



Breast Cancer

In the ACC comments, we explain in detail why breast cancer is an appropriate endpoint to include as part of the epidemiological weight of evidence for carcinogenicity but is not appropriate to use for quantitative risk assessment.

There was a substantial number of missing cases in the NIOSH breast cancer incidence interview study, recognized by the study authors (Steenland et al. 2003). The bias concern is that these cases are more likely to be among short term, low cumulative exposure workers, who are more

difficult to locate, and therefore would have deficits of cancer in the low exposure category, suggesting a positive trend. The magnitude of missing data and potential bias argues against using these data in quantitative risk assessment. Breast cancer mortality results, also examined by NIOSH, do not suffer from underascertainment. These data are more consistent with the standard CPH model as was applied by Valdez-Flores et al. (2010). The standard CPH model, on the other hand, as employed by TCEQ for lymphoid cancers and generally applied to occupational epidemiology studies, more appropriately models a gradual increase in risk with increasing exposure.

The submitted ACC comments (at p. 20, Table 3) further note that in the case of breast cancer, the spline model fit by EPA, the corresponding corrected LR-test p-value of 0.04 indicates that fit is only marginally adequate and is in fact worse than that ($p = 0.02$) associated with the standard CPH model fit to the breast cancer data. Thus, if the California SRP agrees with OEHHA that breast cancer should be included in quantitative assessment, then we urge the SRP to recommend OEHHA to use the standard CPH model fit to the fully ascertained breast cancer mortality that is available in the EPA IRIS (2016).

Ground-truthing model selection

TCEQ's ground-truthing exercise is a more objective method than IRIS's visual fit comparisons to address how well the models predict the actual number of cancer mortalities. TCEQ demonstrated that the CPH model prediction for the full NIOSH cohort is more accurate than for the IRIS 2-slope model. This is also true when a healthy worker effect of 15% is included to represent differences between the NIOSH and general population even though the authors of the NIOSH study conclude there was no HWE. In addition, this conclusion remains true even when different methods for calculation of confidence intervals are used. Importantly, the CPH model prediction is also more accurate for each exposure quintile including the lowest exposure category that EPA considers most relevant for the general population.

The OEHHA IUR should be corrected to indicate that the TCEQ model has excellent overall and local fit based on the TCEQ's prediction analysis, which considers a possible HWE effect as a reasonable surrogate for differences that might exist between the general US population and the NIOSH worker cohort.

Summary

We appreciate OEHHA's efforts to independently evaluate the IRIS assessment. As part of this effort, we urge OEHHA to seriously consider our comments together with the more detailed ACC comments that address OEHHA's new analysis and evaluations. The attached ACC comments provide additional references and analysis supporting the following key points that summarize why dose-response analysis using a single log-linear CPH model has greater biological plausibility and is more consistent with the observed epidemiology data:

- The USEPA's 2-slope model is comprised of a steep slope in the low-dose region with high-dose plateau. This appears to be an artifact of embedded decisions made in the modeling, in particular:
 - Combining men's & women's data exhibiting dramatically different exposure-response behaviors
 - Incorrect statistics, misleading visual fit comparisons, over-reliance on biologically implausible log-cumulative models
- A Steep slope in low dose region is inconsistent with the epidemiology data.
 - Signals for LH, lymphoid and breast cancer are weak and inconsistent across available studies.
- A steep slope in the low-dose-region is inconsistent with the biological evidence
 - Genotoxicity for EtO do not exhibit this behavior.
 - EtO toxicokinetics do not exhibit the behavior of the EPA's steep initial slope.
 - The carcinogenicity data for ethylene and EtO do not exhibit this behavior.
- EPA's 2-slope model overpredicts risk
 - Overestimating cases in the range of observation.
 - The resulting IUR predicts unacceptable excess risk in ambient air, exhaled air and fruits
 - As such, the use of USEPA's IUR to assess, manage, and communicate risks from EtO is not recommended.
- The log-linear CPH model as performed by TCEQ is preferred
 - Accurately predicts the number of cancer cases in range of observation for the NIOSH cohort.
 - Is approximately linear in the low-dose range without exhibiting a plateau that is inconsistent with relevant mechanistic data.
 - Is a standard model used for epidemiology and is more representative of the epidemiological weight of evidence.
 - The behavior is consistent with the underlying genotoxicity, carcinogenicity and toxicokinetics of EtO.

All references cited are listed in the attached detailed ACC comments on the Draft IUR.

APPENDIX C

February 2, 2024, Abby Li oral comments presented to Scientific
Review Panel on Toxic Air Contaminants

Oral Comments on the OEHHA DRAFT IUR

Statistical and Biological Considerations


Abby Li, Bhaskar Gollapudi, Kenneth Bogen, Steave Su, James Bus, Jane Teta
*Written Comments and Published Research Supported by the American
Chemistry Council's Ethylene Oxide Panel*

Presented to the California Air Resources Board
Scientific Review Panel on Toxic Air Contaminants
February 2, 2024 Public Meeting

Key Issue: Model Selection

EPA IRIS MODEL: 2-piece linear spline model

Steeper initial slope + shallower second slope (2-slope model)



Not plausible based on the biological and epidemiological data for EtO


EPA IRIS rationale for 2-slope linear model

- Statistical fit
- Visual fit
- Significant log cumulative exposure models

EPA IRIS rationale for 2-slope linear model Is Flawed

- ▶ Statistical fit -incorrect p-values
- ▶ Visual fit -figures not fit for purpose
- ▶ Significant log cumulative exposure models -
considered biologically implausible by EPA IRIS

Statistical correction ($p=0.14$) for Lymphoid EPA IRIS $p=0.07$ did not account for the knot




Corrected p-values for TCEQ's Standard CPH and EPA's 2-slope model are comparable

- ▶ TCEQ CPH model ($p=0.22$) \approx IRIS 2-slope model ($p=0.14$)
 - ▶ TCEQ Peer reviewers with expertise in statistical modeling for risk assessment agreed with the correction
- ▶ The standard CPH model has the advantage of being a simpler (**more parsimonious**) single-slope model

IRIS “visual fit” figures do not convey the actual data that were fit

IRIS 2-slope model
($p=0.14$)

Standard CPH
model ($p=0.22$)




The Y-axis is Relative Rate (RR): Conclusions about under- or over-estimation based on comparisons along the y-axis cannot be made

Common error:

“...model selected by the TCEQ substantially *underestimates* the nonparametric categorical RR estimates.”

Example from Public comments to TCEQ (p. 59)

<https://www.tceq.texas.gov/downloads/toxicology/dsd/comments/eto-public-comments.pdf>



Based on flawed visual comparisons,
the Draft IUR incorrectly concludes:

“**Other models, including the log-linear models** (e.g., Cox regression) and the models using categorical data or exposure transformations, generally resulted in slopes that **appeared to dramatically over- or under-predict the actual study results,** especially in the lower-exposure ranges”

Based on flawed visual comparisons,
the Draft IUR incorrectly concludes:

“Other models, including the log-linear models (e.g., Cox regression) and the models using categorical data or exposure transformations, generally resulted in slopes that appeared to dramatically over- or under-predict the actual study results, especially in the lower-exposure ranges”

In fact, the TCEQ CPH model accurately predicts the observed number of lymphoid mortalities in the NIOSH study, while the EPA IRIS model statistically significantly overpredicts. This is true in the lower exposure ranges and overall.

EPA SAB (2015) emphasized

*“Any model that is to be considered reasonable for risk assessment must have a **dose-response form that is both biologically plausible and consistent with the observed data.**”*

Standard CPH model is more consistent with the Biological Evidence

(Detailed ACC Comments to SRP and OEHHA)

- ▶ Mutagenicity is the presumed MoA for EtO Carcinogenicity
- ▶ EtO is a direct-acting alkylating agent
 - ▶ Metabolic activation not required for its reactivity
 - ▶ Detoxified via GSH conjugation and epoxide hydrolysis
- ▶ DNA adduction is the molecular initiating event
 - ▶ Repair processes expected to afford protection
- ▶ EtO is a weak mutagen
 - ▶ Requires high doses and long exposure durations
- ▶ Dose-response data on TK, DNA adduction, mutagenicity, and carcinogenicity (ethylene and EtO) support the CPH model, but NOT a 2-piece spline model with steep initial slope

Recommendation: An IUR should be developed using a standard log-linear CPH model

- ▶ **Statistical Considerations:** Parsimonious model that better predicts the actual data.
- ▶ **Biological Plausibility:** Model is consistent with the underlying genotoxicity, carcinogenicity and toxicokinetics of EtO
- ▶ **Consistency with Observed data:** Is more representative of the NIOSH study and the epidemiological weight of evidence
- ▶ **Values needed to derive IUR based on Standard CPH are readily available**
 - ▶ Lymphoid Mortality (TCEQ and EPA IRIS)
 - ▶ Breast Cancer Mortality (EPA IRIS and Valdez-Flores et al. 2010)
 - ▶ Breast Cancer Incidence (EPA IRIS, but missing data)



Thank you for your attention

Questions?

APPENDIX D

February 2, 2024, Rick Reiss oral comments presented to
Scientific Review Panel on Toxic Air Contaminants

Exponent®

x

Comments on OEHHA IUR for Ethylene Oxide

Rick Reiss, Exponent


On Behalf of the Ethylene Oxide
Sterilization Association

February 2, 2024

EPA's Dose-Response Model Vastly Overpredicts Lymphoid Mortalities in the NIOSH Study


- TCEQ conducted a reality-check of the lymphoid mortality predictions
 - Neither TCEQ nor the industry have access to the breast cancer incidence data
- TCEQ estimated the lymphoid mortalities predicted by EPA's model compared to the observed mortalities
 - EPA's model vastly overpredicts the mortalities
 - We recast the results in terms of excess mortalities which more clearly shows the overprediction
- EPA and OEHHA cite TCEQ's failure to account for a healthy-worker effect (HWE)
 - However, TCEQ performed a sensitivity analysis assuming a HWE and their conclusion still holds

Overprediction of EPA's Dose-Response Model



1. Loglinear (TCEQ) - 15-year lag (MLE)
2. Loglinear (TCEQ) - 15-year lag (95% UCL) TCEQ uses to estimate risks
3. USEPA - Linear Spline - 15-yr lag (MLE) - USEPA Table 4-4 Knot @ 1,600 ppm-days
4. USEPA - Linear Spline - 15-yr lag (95% UCL) - USEPA Table 4-4 Knot @ 1,600 ppm-days

Overprediction of EPA's Dose-Response Model Assuming a HWE



1. Loglinear (TCEQ) - 15-year lag (MLE)
2. Loglinear (TCEQ) - 15-year lag (95% UCL) TCEQ uses to estimate risks
3. USEPA - Linear Spline - 15-yr lag (MLE) - USEPA Table 4-4 Knot @ 1,600 ppm-days
4. USEPA - Linear Spline - 15-yr lag (95% UCL) - USEPA Table 4-4 Knot @ 1,600 ppm-days

APPENDIX E

February 2, 2024, Jane Teta oral comments submitted to
Scientific Review Panel on Toxic Air Contaminants

Oral Comments on the OEHHA DRAFT IUR

Epidemiological Considerations

Jane Teta, Bhaskar Gollapudi, Kenneth Bogen, Steave Su, James Bus, Abby Li
Written Comments and Published Research Supported by the American Chemistry Council's
Ethylene Oxide Panel

Presented to the California Air Resources Board
Scientific Review Panel on Toxic Air Contaminants
February 2, 2024 Public Meeting

The IRIS assessment for ethylene oxide (EtO) includes a steep increasing risk at low exposures, implying that EtO is a potent carcinogen. The NIOSH study of sterilant workers and the UCC study of chemical workers do not support this implication. The absence of lymphoid cancer excesses in the UCC study should not be dismissed. This study does not support the shape of the model selected for risk assessment.

In the NIOSH study, there is no overall excess of lymphoid cancer mortality nor breast cancer incidence or mortality. These findings cannot be attributed to the Healthy Worker Effect (HWE), as this study population has had extensive follow up. In worker-to-worker comparisons, increased lymphoid cancer was observed in the NIOSH study, for males only, at the highest exposure group. For females, there was no increase and indication of a negative trend with increasing exposure. An excess was observed for breast cancer mortality, again in the highest exposure category.

The conclusions of the NIOSH authors with respect to cancer mortality findings were very tempered.

“Positive-exposure response trends were found for males only. Reasons for the sex specificity of this effect are not known. There was also some evidence of a positive exposure-response for breast cancer mortality.”

The positive breast cancer incidence findings were also cautiously interpreted by the NIOSH authors who stated:

“Our data suggest that EtO is associated with breast cancer, but a causal interpretation is weakened due to some inconsistencies in exposure-response trends and possible biases due to non-response and incomplete cancer ascertainment.”

There was a substantial number of missing cases in the NIOSH breast cancer incidence study, used by EPA for quantitative risk assessment. The concern is that these missing cases are more likely to be among short term, low cumulative exposure workers, because they are more difficult to locate. There would then be deficits of cancer in the low exposure categories,

suggesting a positive trend and increases in the highest exposure category, which were reported in the NIOSH publication. The magnitude of missing data and potential bias argues against using these data in quantitative risk assessment.

OEHHA responded to ACCs argument that, since smokers are highly exposed to EtO, smoker studies should have confirmed a relationship with lymphoid cancers and they do not. OEHHA cites two smoker studies published in 2012. The results of these studies are either not consistent with NIOSH findings or not relevant to the outcome of lymphoid cancers. The expected relationship between smoking and lymphoid cancer, based on the IRIS risk model, has not been confirmed by OEHHA or the Surgeon General (report of 2014).

In summary,

The EPA risk assessment supported by OEHHA implies that EtO is a potent carcinogen with steep slope at low exposures, a conclusion unsupported by published epidemiology studies and the absence of increased risk for lymphoid tumors in smokers.

NIOSH breast cancer incidence data is inappropriate for modelling due to absence of increases overall and potential bias resulting from a substantial number of missing cases. We recommend the use of the standard CPH model for dose-response assessment.

Oral Comments on the OEHHA DRAFT IUR

Epidemiological Considerations

Jane Teta, Bhaskar Gollapudi, Kenneth Bogen, Steave Su, James Bus, Abby Li
*Written Comments and Published Research Supported by the American
Chemistry Council's Ethylene Oxide Panel*

Presented to the California Air Resources Board
Scientific Review Panel on Toxic Air Contaminants
February 2, 2024 Public Meeting

Foreword

- Self introduction
 - Active in EtO epidemiology and risk assessment for over 30 years
 - Co-authored the UCC study publications
 - Published numerous papers on the use of epidemiology in quantitative cancer risk assessment
- OEHHA's review of EtO epidemiology
 - An onerous challenge, building on the work of EPA, without access to the NIOSH data

Comments on OEHHA's Review of EtO Epidemiology

Epidemiology studies do not suggest steep increasing risk at low cumulative exposures, i.e., a potent carcinogen

NIOSH and the UCC data sets of workers exposed to Ethylene Oxide

Endpoint (Males only)	NIOSH (Steenland et al., 2004)	UCC (Swaen et al., 2009)
Lymphoid Tumors (NHL, lymphocytic leukemia, multiple myeloma)	27	17
All Workers	7,634	2,063
% Deceased	19%	51%
Avg. follow-up	25 yr.	37 yr.
Avg. ppm-yr. exposure	27	67

Epidemiologic evidence does not support IRIS model of a potent carcinogen

➤ **NIOSH Sterilant workers (Steenland et al., 2003, 2004)**

- No overall excesses in lymphoid cancer mortality or breast cancer mortality/ incidence in general population comparisons
- Increased lymphoid cancer mortality for males only at highest exposure group in select worker to worker comparisons by exposure levels
- Lymphoid risk for women decreases with increasing exposure

➤ **UCC Chemical workers (Swaen et al., 2009)**

- No increased lymphoid cancer mortality in general population or worker-to-worker comparisons by exposure levels
- Additional analyses (lagged, categorical) in Valdez-Flores et al. (2010)

Published epidemiology data conflicts with results of IRIS model

IRIS visual fit and unit risk analysis combined male and female data with opposing associations

	Males	Female
NHL SMR	1.29 (95% CI: 0.78-2.01)	0.73 (95% CI: 0.38-1.29)
NHL 13,500+ppm-d SMR	2.37* (n = 8)	0.37 (n = 1)
Lymphoid CPH cum exp	p = 0.06, positive slope	p = 0.78, negative slope
Lymphoid CPH categorical cum exp	OR = 1.00, 2.45, 1.85, 2.44*	OR = 1.00, 2.05, 1.25, 0.87
* Statistical significance		

“Positive exposure-response trends for lymphoid tumours were found for males only. Reasons for the sex specificity of this effect are not known.” (Steenland et al., 2004)

**Breast Cancer Incidence Data should
not be used for Quantitative Risk
Assessment**

“Our data suggest that EtO is associated with breast cancer, but a causal interpretation is weakened due to some inconsistencies in exposure-response trends and possible biases due to non-response and incomplete cancer ascertainment.”

Steenland et al. (2003)

Missing Breast Cancer Cases in IRIS Analysis

- ▶ 319 identified cases, 367 expected based on general population, therefore
 - ▶ **48** or more missed cases
- ▶ 233 cases out of 319 women interviewed (32% women did not participate, mostly due to inability to locate)
 - ▶ **86** more cases lost
- ▶ If all women were interviewed, the analysis would have included **134 or more** breast cancer cases in addition to the 233

Breast cancer incidence

- ▶ Substantial number of missing cases in overall study and interviewed substudy
- ▶ Serious concern that case identification more complete among long-term more highly exposed workers than among short term lower exposed workers
- ▶ Consequence: apparent positive slope, regardless of model

Use of breast cancer epidemiology data for dose-response assessment

- ▶ NIOSH Breast cancer incidence data **should not** be used for quantitative risk assessment purposes
 - ▶ Steenland et al. (2003) refers to findings as suggestive with additional uncertainties
 - ▶ Missing cases
 - ▶ Data is not publicly available
- ▶ NIOSH Lymphoid and Breast cancer **mortality** data are complete and more consistent with the standard CPH model

Epidemiology studies of smokers are inconsistent with IRIS model

- ▶ Smokers have ten times more EtO exposure than non-smokers
- ▶ However, studies of smokers do not indicate a relationship with lymphoid cancers, let alone a steep risk at low exposures
- ▶ Studies of smokers cited by OEHHA's report lymphoid increases among women only (Diver et al. 2012), the opposite of NIOSH findings, or report (Kroll et al., 2012) excesses of a different disease (Hodgkins lymphoma, rather than Non-Hodgkins lymphoma)

OEHHA's examination of potential biases in NIOSH study is applauded

- ▶ HWE and HWSE are not of particular concern
- ▶ OEHHA review of NIOSH exposure assessment is incomplete
 - ▶ Focuses only on post-1978 estimates
 - ▶ Misses exposure errors on pre-1978 estimates

Epidemiological Evidence: Conclusions

- ▶ Epidemiologic evidence does not support IRIS model of a potent carcinogen
 - ▶ NIOSH Sterilant study
 - ▶ UCC cohort study
 - ▶ Lack of increased risk for lymphoid tumors in smokers
- ▶ NIOSH breast cancer incidence data is inappropriate for modelling
- ▶ Standard CPH model for dose-response assessment is recommended
 - ▶ More consistent with the existing epidemiology
 - ▶ Use lymphoid deaths as the target effect